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YOU 
By Edgar A. Guest 
 
 
You are the fellow that has to decide 
Whether you’ll do it or toss it aside. 
 
You are the fellow who makes up your mind 
Whether you’ll lead or linger behind; 
 
Whether you’ll try for the goal that’s far, 
Or just be contented to stay where you are. 
 
Take or leave it, here’s something to do! 
Just think it over—it’s all up to you. 
 
What do you wish? To be known as a shirk, 
Or known as a good man who’s willing to work? 
 
Scorned as a loafer, or praised by your chief, 
Rich man or poor man or beggar or thief? 
 
Eager and earnest or dull through the day? 
Honest or crooked? It’s you who must say. 
 
You must decide in the face of the test 
Whether you’ll shirk or live it your best.
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This thesis  focuses on clinically relevant evaluations of natural and synthetic grafting materials.  
The intent was to develop a sound methodology  to evaluate biomaterials considered for clinical 
use and to provide an insight on the different grafting stategies to enhance bone formation.  
The most traditional technique to bridge large defects involves the use of segments of frozen 
allogenic cortical bone.  In this instance, it is crucial that cortical allografts retain biomechanical 
properties, allowing the repaired bone to withstand forces generated during weight bearing. In the 
first part of this study, the influence of long-term storage of allografts frozen in saline or dry 
containers was evaluated in bending and torsion.  Within pairs of canine metacarpal bones, 
metatarsal bones, and ribs, one bone was frozen in a dry plastic container, while the other was 
immersed in a normal solution of sodium chloride for one year.  The energy absorbed at failure 
and the ultimate displacement of all bones tested in bending were increased by 25%, to 30% and 
18%, to 24% respectively, when the bones were frozen in isotonic saline solution.  
Corticocancellous grafts frozen in normal saline solution are biomechanically less fragile and 
brittle than grafts stored in plastic without saline solution. 
Where biomechanical strength is not crucial, fresh autogenous cancellous graft is still considered 
the ”golden standard” when evaluating other biomaterials.  However, the morbidity and 
additional surgical time associated with its collection, as well as the limited supply in each 
patient, have stimulated the search for substitutes. These have been classified as osteoinductive or 
osteoconductive, depending on their properties.   
The second part of the study dealt with an os teoinductive graft substitute extracted from a human 
osteosarcoma cell line. The osteoinductive properties of this bone-inducing agent (BIA) were 
tested in the Latissimus Dorsi of five dogs.  Because of its clinical relevance, we also evaluated 
this material after orthotopic implantation, in unicortical femoral defects created in four dogs.    
The effects of BIA were compared with bovine collagen I (the carrier), a gelatin capsule 
(negative control), and fresh autogenous cancellous graft (positive control), after orthotopic and 
heterotopic implantation.  Bone formation was evaluated via serial radiographs, dual energy X-
ray absorptiometry, histology, and histomorphometry.  Ten milligrams of BIA did not induce 
bone formation six weeks after heterotopic implantation and failed to promote bone healing eight 
weeks after orthotopic implantation in dogs.  The discrepancy between these results and those 
previously obtained in rodents may be related to immunogenic factors or to the dose of BIA used 
in this study. 
The third part of the study comprised osteoconductive biomaterials considered for potential use in 
impaction revision hip arthroplasty in man.  The general purpose of this study was to evaluate the 
use of biomaterials to expand or replace allografts, with a specific interest in the revascularization 
and incorporation of impacted morselized grafts.  In study III, a model was designed to simulate 
the environment encountered in revision hip arthroplasty and study the biological properties of 
several impacted aggregates of large particles in the same animal (higher vertebrate). The model 
was evaluated in Study III and applied to study biomaterials in Studies IV and V.   
A miniature impactor was designed to produce pellets of aggregates at a compactive effort 
similar to that generated in clinical impaction grafting.  Twenty-two sheep underwent 
implantation of pellets into six metaphyseal defects in both rear limbs (Study IV).  Another eight 
sheep underwent surgical implantation of four pellets in metaphyseal defects (Study V). Defects 
were sealed with polymethylmethacrylate in both phases. Healing of the defects was evaluated at 
seven weeks (n=11) and 14 weeks (n=19) with computed tomography, histology, and 
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histomorphometry.  Complications in the initial phase (sheep in Study IV) included four femoral 
fractures and migration of the cement seal (18/102 defects).  No complications occurred in the 
later phase (sheep in Study V).  Although no difference was found between left and right limbs, 
osteogenesis and incorporation of biomaterials varied between implantation sites. Treatment site 
allocation was randomized according to a Latin square design for comparison of grafting 
materials.  This model allows evaluation of several impacted aggregates (including large 
particles) in the same animal. It is particularly suitable for analyzing the biological properties of 
grafting materials prior to evaluation under loading conditions. 
The osteoproductive properties of a new silicate-free idealized morselized bioactive glass 
(Corglaes®), alone or combined with allograft were evaluated in Study IV. Particle size 
distribution of all aggregates (except the autograft) approached the ideal logarithmic grading line, 
and all implants were impacted at a standard compactive effort.  Treatment groups consisted of 
(1) empty defect (negative control), (2) autograft (positive control), (3) allograft (clinical control), 
(4) allograft idealized with Corglaes®, (5) 50 /50 allograft / Corglaes®, and (6) Corglaes®.  
Healing of the defects was evaluated at seven weeks (n=6) and 14 weeks (n=16) with computed 
tomography, histology, and histomorphometry.  Remnants of Corglaes® were found within one of 
the defects 7 weeks after implantation.  Defects filled with mixtures containing 50% or 100% 
Corglaes® were less dense, and contained less bone and more fibrous tissue than defects with 
allograft, autograft, or allograft idealized with Corglaes®.  Allograft idealized with Corglaes® 
may be considered for impaction grafting in revision hip arthroplasty, as well as local delivery of 
antibiotics.  However, further studies and potential revision of the agent are required before 
mixtures containing concentrations of Corglaes® equal to or higher than 50% can be 
recommended.  
In Study V, the model was slightly adjusted to investigate, the properties of idealized, impacted 
tricalcium phosphate-hydroxyapatite (TCP-HA) aggregates, varying in chemical composition 
(ratio of TCP to HA) and particle size distribution (idealization with 8 versus 3 particle size 
ranges).  Treatment groups consisted of: (1) allograft (clinical control), (2) 50/50 allograft / 
80%HA/20%TCP idealized with 8 particle size ranges, (3) 50/50 allograft / 80%TCP/20%HA 
idealized with 8 sizes and (4) 50/50 allograft / 80%HA/20%TCP idealized with only 3 particle 
sizes. At 14 weeks, the pixel value measured with computed tomography in all defects containing 
synthetic agents was higher than in defects filled with allograft alone (p<0.01).  Defects 
containing the idealized mixture of 80%HA/20%TCP granules (group 2) achieved lower 
histological scores and contained less bone than the clinical control (p<0.05), whereas groups 3 
and 4 did not differ from the control.  Although all synthetic agents were osteoconductive, our 
results suggest that increasing the ratio of TCP over HA and limiting the number of particle size 
ranges to 3 instead of 8 improve the performance of impacted aggregates as graft expanders.  
Evaluation under loading conditions of morselized allograft expanded with 80%TCP/20%HA 
(BoneSave®) in 3 particle size ranges is warranted.  
 
 
?
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This dissertation is based on the following publications which are referred to in the text by their 
Roman numerals. 
 
1. Study I: Griffon DJ, Wallace LJ, Bechtold JE: Biomechanical properties of  canine 
corticocancellous bone frozen in normal saline solution. Am J Vet Res 
1995;56(6):822-825. 
 
2.  Study II: Griffon DJ, McLaughlin R, Hoskinson J: Effects of a Bone Inducing Agent 
derived from a cultured human osteosarcoma cell line after orthotopic and 
heterotopic implantation in the dog. VCOT 1996;9:22-28. 
 
3.  Study III: Griffon DJ, Dunlop DG, Howie CR, Pratt JNJ, Gilchrist TJ, Smith N: An ovine 
model to evaluate the biological properties of impacted morsellised bone graft 
substitutes.  J Biomed Mater Res 2001;56(3):444-451. 
 
4. Study IV: Griffon DJ, Dunlop DG, Howie CR, Gilchrist T, Salter DM, Healy DM: Early 
dissolution of a morsellised impacted silicate-free bioactive glass in metaphyseal 
defects. J Biomed Mater Res – Applied Biomater 2001;58(6):638-644. 
 
5.  Study V:  Pratt JNJ, Griffon DJ, Dunlop DG, Smith N, Howie CR: Impaction grafting with 
idealised allograft and tricalcium phosphate – hydroxyapatite: Incorporation 
within ovine metaphyseal defects. Biomater 2002; 23: 3309-3317. 
 
?
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3.1.  TERMINOLOGY AND DEFINITIONS 
 
Allograft (adjective, allogeneic): living tissue transferred between two genetically different 
individuals of the same species (Stevenson 1999). Gorer was the first, in 1961, to suggest 
that allograft should replace the previously used term homograft (Gorer et al. 1961).   
 
Alloimplant: nonviable tissue transferred between two individuals of the same species. Most 
allografts are actually alloimplants (Fitch et al. 1997). 
 
Autograft (adjective, autogenous or autogeneic): a graft moved from one site to another within 
the same individual. 
 
Bioactive: refers to a material that induces specific biological activity, as opposed to bioinert 
(Williams 1987). 
 
Bone Morphogenetic Protein (BMP): generic name for osteoinductive proteins extractable from 
bone matrix with chaotropic agents, such as 4M-guanidine hydrochloride, and able to 
induce de novo bone formation (Urist 1990). 
 
De novo bone formation: bone formation in a site devoid of osteoprogenitor cells.  
 
Grade (of an aggregate): refers to the particle size distribution of the aggregate. A well-graded 
aggregate include particles of variable sizes, with a particle size distribution approaching 
the ideal curve or line (depending on the shape of particles) consistent with the particulate 
aggregate theory.  Poorly graded aggregates are of more uniform size. 
  
Heterotopic: refers to the placement of a graft in an anatomically inappropriate site (i.e. not in 
contact with bone). Also known as ectopic placement.  
 
Idealization: correction of the particle size distribution of an aggregate to match the ideal 
logarithmic curve described by Fuller for spherical particles.  According to the particulate 
aggregate theory, a modified curve should be used for irregular particles (Craig 1993). 
  
Implant: nonviable material, such as bone, that has been frozen, freeze-dried, or sterilized by 
irradiation (Urist 1980, Burwell 1994).  
 
Isograft (adjective, isogeneic or syngeneic): live tissue transferred from one twin into an identical 
(monozygotic) twin (Urist 1980, Stevenson 1999). 
 
Orthotopic: Refers to anatomically appropriate (i.e. within bone) placement of a graft, as opposed 
to heterotopic. 
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Osteoconduction: process whereby microscopic and macroscopic scaffolding is provided for 
inward migration of cellular elements involved in bone formation (e.g. mesenchymal cells, 
osteoblasts, osteoclasts, and vasculature). Implanted bone acts as a structural framework 
(“trellis”) for bone ingrowth (Fitch et al. 1997). 
 
Osteogenesis: in a general sense, osteogenesis refers to bone formation with no indication of 
cellular origin: new bone may originate from live cells in the graft or cells of host origin 
(Stevenson 1999). In a stricter and more commonly used definition, osteogenesis refers to 
bone formation by transplanted living cells (Mulliken et al. 1984, Fitch et al. 1997). In this 
thesis, the latter definition is used. 
 
Osteoinduction: process of recruitment from the surrounding bed of mesenchymal-type cells, 
which then differentiate into cartilage-forming and bone-forming cells under the influence 
of a diffusible Bone Morphogenetic Protein (Urist 1980, Stevenson 1999). 
 
Osteoproduction: used here to describe bone proliferation resulting from the combined properties 
(i.e. osteoinductive, osteoconductive, and/or osteogenic properties) of a grafting material. 
This term has also been used to describe the properties of class A bioactive materials, such 
as bioactive glass, that enhance both the proliferation and the differentiation of progenitor 
cells (Hench 1998, Wilson & Low 1992). As opposed to class B bioactive materials, such as 
synthetic hydroxyapatite, the properties of which are limited to osteoconduction.  
 
Osteotropism: biodynamic effects of hydroxyapatite ceramic in contact with living bone and 
resulting in new bone formation in direct contact with the surface of the ceramic, without 
formation of a separating fibrous layer. Also called bonding osteogenesis (Heise et al. 1990, 
Burwell 1994). 
 
Transplant: refers to a living graft, as opposed to implant (Urist 1980, Burwell 1994). 
 
Xenograft (adjective, xenogeneic): transfer of viable tissue from a donor of a different species. 
Has replaced the term heterograft (Gorer et al. 1961). 
 
Xenoimplant: nonviable tissue transferred between individuals of different species. 
 
 
3.2. ABBREVIATIONS 
 
AATB:  American association of tissue banks 
AIDS:   Acquired immune deficiency syndrome 
AW-GC:  Apatite and wollastonite glass ceramics 
BIA:   Bone-inducing agent  
BMP(s):  Bone morphogenetic protein(s) 
CaO:   Calcium oxide 
Coll:  Collagen 
CRG:   Controlled release glass 
CT:   Computed tomography 
EDTA:  Ethylenediaminetetraacetic acid 
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DBM:   Demineralized bone matrix 
HA:   Hydroxyapatite 
HIV:   Human immunodeficiency virus 
kDa:  kiloDalton 
KGy:   kiloGray 
MAR:  Mineral apposition rate 
MTC:  Metacarpal bones 
MTT:  Metatarsal bones 
Na2O:   Disodium oxide 
NSS:   Normal saline solution 
OP (s):  Osteogenic protein(s) 
PMMA: Polymethylmethacrylate 
P2O5:   Pyrophosphate 
SiO2:   Silica 
SEM:  Standard error of the mean 
TCP:   Tricalcium phosphate 
TGF:   Transforming growth factor 
?
 7 
????????????????
 
 
Over the last decades, a great deal of research has focused on therapies for enhancing bone 
regeneration.  Their clinical applications are indeed very diverse and expanding to follow the 
evolution of orthopedic surgery.  Over 500000 bone grafting procedures are performed every 
year in the United States alone, and about twice as many are performed in the rest of the world 
(Clayton Shors 1999).  Stimulating bone production may be applied to the management of 
fractures, nonunions, and osteomyelitis. Other orthopedic indications include limb lengthening, 
reconstructive procedures following tumor resection, arthrodeses, and osteointegration of joint 
replacement prostheses.  The clinical use of these techniques actually extends beyond the field of 
orthopedics to include periodontal, maxillofacial and neurosurgeries.  Much progress has been 
made simultaneously with our improved understanding of bone healing, leading to the 
elaboration of techniques targeting various factors involved in bone regeneration (Figure 1).   
 
 
OSTEOINDUCTION
OSTEOCONDUCTION
BIOMECHANICAL 
MODIFICATIONSOSTEOGENESIS
GENE THERAPY
ELECTROMAGNETIC 
FIELDS
ENHANCING OSTEOPRODUCTION
ULTRASOUNDS
 
 
Figure 1: Techniques stimulating bone formation 
 
 
The importance of the biomechanical environment on bone healing was soon realized, promoting 
the development of fracture fixation techniques.  More recent examples of biomechanical 
modifications to bone healing include distraction osteogenesis (Ilizarov 1990; Marsh et al. 1997) 
and axial dynamization of long bone fractures (Egger et al. 1993; Richardson et al. 1995).  Other 
biophysical alternatives to enhance fracture repair involve the use of low-intensity pulsed 
ultrasonography (Hadjiargyrou et al.1998) and electrical stimulation (Ryabi 1998).  Although 
their mechanisms of action remain somewhat unclear, these techniques have been used in man to 
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obtain healing of nonunions, accelerate normal fracture healing, and increase healing rates in 
patients considered at risk for nonunion, such as smokers or diabetics (Cook 1997).  Some 
experimental data are available concerning the effects of these techniques in dogs, and their 
clinical use is emerging in veterinary orthopedics (Mason & Renberg 2001 a,b).  However, 
among all, bone grafting remains one of the oldest, yet most popular methods to stimulate bone 
formation.  
 
The first alleged tissue transplantation dates back to the fifth century, with the Miracle of St. 
Cosmos and St. Damien, according to which the twin brothers resected a diseased limb from a 
churchwarden and replaced it with the distal extremity of a Moor deceased the same day (Mankin 
et al. 1983; Hanson & Markel 1992).  However, Job van Meekeren was the first to document the 
use of bone graft in 1668.  This Dutch surgeon used a piece of canine skull to replace a skull 
defect in a Russian nobleman.  The operation was successful but resulted in the excommunication 
of the patient by the church (Boer 1988). It was not until the nineteenth century that the clinical 
usefulness of bone grafting was recognized.  Merrem reported on bone transplants in 1810, and 
von Walther performed the first recorded human autogenous bone graft in 1820.  While Ollier, in 
1867, formulated the scientific principles of bone grafting based on his experimental work in 
France (Ollier 1867; Schweiberer et al. 1989), MacEwen, a student of Lister, performed a 
successful human bone allograft under aseptic conditions in 1878, in the Infirmary of Glasgow 
(Chase & Herndon 1955). In the early 1900s, the extensive research performed in Berlin by 
Axhausen (Burwell 1994) on the transplantation of periosteum, marrow, and bone in rats, rabbits, 
and dogs provided a bedrock of knowledge that even today remains largely unchallenged.  Barth 
was the first to describe the process of new tissue invading along channels created by invasive 
blood vessels or along pre-existing channels in the transplanted bone (Barth 1893).  This process 
was called “schleichender ersatz”, a term literally translated by Phemister in 1914 as “creeping 
substitution”, to describe a dynamic reconstructive and healing process for bone transplantation 
(Burchardt 1983).  In 1911, Albee, a Professor of Surgery in the New York Postgraduate Medical 
School, initiated the use of living bone grafts as internal splints and reported on thousands of 
clinical successes a few years later (Albee 1923).  
 
Bone transplants are now routinely used in human and veterinary orthopedics to promote fracture 
healing, enhance joint fusion, and repair bone defects. Fresh autogenous grafts (Figure 2) are still 
considered a “golden standard” to which other osteoproductive agents are compared.   
 
 
 
 
Figure 2: Fresh autogenous 
cancellous graft harvested from the 
medial proximal tibia of a dog.    
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Indeed, autogenous bone is the most effective material in promoting rapid healing since, 
compared with other materials, it provides viable cells while avoiding immune reactions and 
disease transmission (Fitch et al. 1997).  In small animals, fresh autogenous cancellous bone can 
be harvested from the iliac crest, medial proximal tibia, and proximal humerus, depending on the 
location of the surgical site.  The most common site for collecting cancellous autograft in man is 
the iliac crest.  This procedure is associated with a morbidity rate approximating 25% in humans, 
with major complications, such as herniation or subluxation of the hip, reported in 3- 4 % of 
patients (Younger & Chapman 1989; Damien & Parsons 1991).  Other complications associated 
with the collection of autogenous bone include pain, sepsis, stress fractures (Figure 3), 
intraoperative blood loss, increased surgical time, and limited supply (Damien & Parsons 1991; 
Ferguson J 1996).  Another shortcoming of autogenous cancellous graft consists in its lack of 
biomechanical strength, which precludes its use as a structural graft. 
 
 
 
 
 
To palliate these limitations, the use of allogeneic bone has become popular.  Bone can be 
harvested from live donors (femoral heads during primary hip arthroplasty in man) or cadavers, 
processed and stored.  Interest in methods of preserving and storing bone originates from the 
experimental work of Bauer who, in 1910, showed that bone refrigerated for as long as three 
weeks could be successfully transplanted in dogs (Bauer 1910).  Bone banking techniques for 
human use were subsequently developed by Bush and Wilson during World War II in New York 
and about 30 years later in veterinary orthopedics (Johnson 1988; Burwell 1994).  Human 
autogenous cancellous and cortical bone is now available, allowing surgeons to select the type 
and exact dimensions of implant required at any time.  Canine bone and connective tissue 
allografts have recently become commercially available in the United States.  In most other 
countries, however, the inconvenience of collection, processing, and storage with a limited shelf 
life make bone banking impractical even in large referral practices.  Nevertheless, segments of 
cortical bone constitute the most common type of allograft in veterinary orthopedics (see section 
5.1.1.). These are used as structural grafts to reconstruct severely comminuted fractures and in 
limb salvage procedures after tumor excision (Alexander 1983; Larue et al. 1989).  The 
Figure 3: Postoperative fracture of a 
canine proximal tibia (arrows).   
Fresh autogenous cancellous graft had 
been harvested from the proximal tibia for 
a tarsal arthrodesis. A splint was placed 
around the distal limb to support the tarsus 
(Courtesy of JK Roush). 
 
? 
? 
 10 
incorporation of these grafts is slow and incomplete, increasing the risks of fatigue fracture 
(Henry 1981, Friedlander 1987; Johnson AL et al. 1992; Stevenson 1999). In dogs, infection rates 
as high as 40% in limb salvage procedures have affected interest in this type of graft (Dernell et 
al. 1998; Straw et al.1996).  Similar complications in man have stimulated the search for 
alternative strategies to cortical allografting (Mankin et al. 1984; Thompson et al. 1993; Dick & 
Strauch 1994;).  An example involves use of biomechanical forces to stimulate bone regeneration 
(Figure 1): the reconstruction of large defects can now be achieved by distraction osteogenesis 
and bone transport techniques.  Comparable trends are currently emerging in the veterinary 
community (Elkins et al. 1993; Lesser 1994; Tommasini Degna et al. 2000).   
 
Although the development of bone graft substitutes and other alternative techniques to stimulate 
bone healing has gained tremendous popularity over the last two decades, interest in this field has 
been around much longer.  Toward the end of the 19th century, some surgeons focused on bone-
derived materials, while others experimented with synthetic agents.  Indeed, the first reported use 
of demineralized bone dates back to 1889, when Senn used xenogeneic, decalcified bone to repair 
canine skull defects (Senn 1889; Covey & Wright 1992).  Three years later, Dreesman obtained 
healing in six of nine bone defects implanted with plaster of Paris (Peltier 1961; Damien & 
Parsons 1991).  These two protagonists set the scene for the directions taken in the development 
of grafting materials: bone-derived versus synthetic, osteoinductive versus osteoconductive 
agents.  
 
Urist pursued Senn’s work developing processing techniques for bone.  Investigators before him 
used ethylenediamine tetra acetic acid (EDTA) in the bone demineralization process, which failed 
to neutralize endogenous neutral proteases, inactivating some of the growth factors within the 
bone matrix. In 1965, Urist replaced EDTA with hydrochloric acid and described ectopic bone 
formation following implantation of demineralized bone matrix in rodents (Urist 1965). This 
served as the basis for the theory of “autoinduction”, which, in 1979, led to the isolation of an 
osteoinductive, low-molecular-weight protein from insoluble bone matrix, named “bone 
morphogenetic protein” or BMP (Urist 1980; Urist et al. 1983).  In an attempt to reduce 
antigenicity and avoid irradiation, Urist also produced an autolyzed, antigen-extracted allogeneic 
bone (AAA bone), with preserved osteoinductivity and a mechanical strength compatible with its 
use in vertebral fusion (Urist 1981a,b). The concept of delivery systems for BMPs originates 
from Sampath and Reddi, who demonstrated in 1981 that neither the postextraction bone matrix 
nor the residue alone induced ectopic bone formation in rodents, but that the osteoinductive 
properties were totally restored by combining both (Sampath & Reddi 1981).  They also 
introduced the homology of osteoinduction in 1983, showing that proteins extracted from human, 
monkey, rat, and bovine extra cellular matrix could all induce bone formation when combined 
with inactive allogeneic bone matrix (Sampath & Reddi 1983).   
 
Further analysis of the BMP fraction contained in the extra cellular bone matrix led to the 
identification of several distinct proteins that, either alone or in combination with other regulatory 
molecules, could induce bone formation (Wolfe & Cook 1994). In 1987, Sampath and colleagues 
isolated an osteoinductive extra cellular matrix-associated protein from demineralized bovine 
bone matrix, which seemed 1000 times more potent than BMP (Sampath et al. 1987). This 
protein was named “osteogenin”.  A year later, Wang et al. purified BMPs for the first time, 
isolating three polypeptides of 16-, 18- and 30-kDa molecular weight from bovine bone.  These 
would eventually be named BMPs 1-3 (Wang et al. 1988).  While purification decreased the 
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likelihood of adverse effect associated with immunogenic impurities, the process was laborious 
and inefficient.  Synthetic osteoinductive agents were therefore developed as soon as purification 
of osteoinductive proteins reached sufficient quantity and homogeneity to provide amino acid 
sequence data. Human complementary DNAs could then be isolated and cloned, and the 
osteogenic protein gene product recovered from host cell-conditioned media.  A significant step 
in characterization of BMPs came in 1988, when Wozney and coworkers isolated human 
complementary DNA clones corresponding to bovine BMP-1, BMP-2A (BMP2), and BMP3 
(Wozney et al. 1988).  All BMPs except BMP-1 belong to the TGF-β superfamily (see section 
5.2), a group that countains more than 15 molecules and continues to grow as new members are 
identified.  At least 10 BMPs have been identified, but two of these proteins have been 
particularly well described in man: recombinant BMP-2 and –7 (OP-1) (Wang et al. 1988, 1990; 
Wozney et al. 1988; Chen et al. 1991; Yasko et al. 1992; Cook et al. 1994, 1995; Geesink et al. 
1999; Mason & Renberg 2001).  Their properties have been studied in several animal 
experiments, and the most advanced human clinical trials have focused on these two growth 
factors (Yasko et al. 1992; Cook et al. 1994, 1995; Kirker-Head et al. 1996; Rowley 2001).  
Geesink and coworkers recently validated the efficacy of BMP-7 in critically sized fibular defects 
created in patients undergoing tibial osteotomy (Geesink et al. 1999).  In this double-blind, 
randomized prospective human clinical trial, 5/6 defects filled with decorticated bone or BMP-7 
(with collagen) healed, whereas none of the defects left empty or filled with collagen alone 
healed.  Such studies are few as the technology is fairly recent and controlled clinical evaluations 
are difficult to perform.  Further randomized prospective clinical trials are therefore warranted to 
justify routine use of osteoinductive agents in human orthopedics (Ladd & Pliam 1999).  
 
Clinical use of osteoconductive materials, in contrast, has gained much popularity. In fact, their 
use dates back further than that of osteoinductive agents, as most allogenic bone grafts 
(undemineralized) are deprived of viable cells and therefore act only as osteoconductive supports.  
The major contribution to the field of osteoconduction made in the 20th century consisted of the 
development of synthetic agents.  Calcium sulfate (plaster of Paris) was one of the first materials 
investigated as a synthetic osteoconductive bone graft substitute. Based on experimental data in 
dogs and clinical experience in humans, Peltier eventually concluded that plaster of Paris is easy 
to use, inexpensive, readily available, stable for filling cavities in bone, and does not inhibit bone 
healing (Peltier 1961).  These findings were later confirmed in canine femoral defects (Elkins & 
Jones 1988). Calcium sulfate is produced by calcining natural gypsum at temperatures of 110 -
130 °C, which removes 75% of the water and results in crystals of irregular shape. Because of its 
natural origin, gypsum may contain impurities, such as iron, magnesium, strontium, lead, and 
other heavy metals, prior to processing (Damien 1991).  Concerns were raised over the potential 
toxic effects, poor osteoconductive properties, fast resorption and poor mechanical strength of 
plaster of Paris, and its clinical use declined as bioactive ceramics gained popularity (Damien 
1991).  The interest in calcium phosphate as hard tissue implants initially evolved around the 
hypothesis that release of calcium ions would stimulate osteogenesis (Leriche & Policard 1928).  
Two main groups of ceramics (see section 5.3.1.) were evaluated: hydroxyapatite (HA) and 
tricalcium phosphate (TCP).  Biodegradability became an issue; TCP was found to resorb within 
days to weeks in vitro and in vivo, whereas HA resorbed slowly (within years), if at all (Klein et 
al. 1983).  To obtain a balanced resorption, one option therefore consisted of mixing both 
materials, anticipating that TCP would provide minerals to feed bone cells while HA would act as 
a scaffold.  This approach has been adopted by many research groups in Europe and in the United 
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States.  Another approach lead to developing macroporous ceramics.  The importance of porosity 
for resorption and effective bone growth into ceramic structures was outlined by Klawitter in 
1971 (Klawitter & Hulbert 1971).  One way of obtaining interconnective pores of at least 100µ 
consisted of using coral as an implant.  The interest in scleractinian corals, such as Gonoporia 
and Gorites, was triggered by their macroscopic porous architecture, approaching that of human 
cancellous bone. Moreover, the use of coral pore structures was taken a step further with the 
development of the replamineform technique (meaning replicated life forms), a hydrothermal 
exchange method for producing ceramic replicas of the coral structure (White et al. 1972).  The 
advantage of the coralline hydroxyapatite produced with this method over coral is that it is devoid 
of any residual organic matter. The use of coral as a source of hydroxyapatite relies on natural 
supplies, which may eventually become insufficient to satisfy a growing market.  Although tons 
of hydroxyapatite are mined from the earth each year as a source of phosphate ion, researchers 
have spent the last 20 years experimenting with hydroxyapatite to attain a level of purity and 
consistency compatible with medical use (Technical monograph 1986; Burwell 1994).  Most of 
the ceramics produced for clinical use are manufactured, and their properties can be adjusted to 
match specific applications.  The resorption rate of HA can be accelerated by increasing porosity, 
but the resultant decrease in biomechanical strength prevents its use as a structural graft.  
Therefore, research interest has focused on improving the biomechanical strength of materials 
while maintaining osteoconductivity, bioactivity, and resorbability (Oreffo & Triffitt 1999).  
Wollastonite-reinforced glass ceramic has been reported to be biomechanically superior to TCP-
HA composites (Kokubo 1993), but bioactive glasses are generally considered too brittle for use  
in large bone defects (Damien & Parsons 1991; Virolainen et al. 1997). Another alternative relies 
on toughening techniques for ceramics, such as designing ceramic-ceramic composites 
incorporating minor amounts of metastable, dispersed second-phase particles (Kuo & Kriven 
1998, Gulgun et al. 1999).  However, none of these materials has been evaluated in vivo.  
 
For many years, developments in the field of biomaterials generally involved trial-and-error 
experiments (Hench 1998).  This approach has often been successful, and over the last 30 years, 
more than 40 different ceramic, metal, and polymeric materials have been used to replace, repair, 
or augment more than 40 different parts of the human body (Hench & Wilson 1993; Ratner et al. 
1996).  This rapidly evolving technology may seem confusing and may challenge the ability of 
clinicians to formulate an informed opinion on emerging therapies.  Orthopedic surgeons should 
objectively review any experimental and clinical data compiled by manufacturers and associated 
research centers to convince themselves of the safety and efficacy of new products.  
Unfortunately, this exercise can be time-consuming and requires a good understanding of 
research protocols.  The wide therapeutic range now offered poses yet another dilemma for 
clinicians.  While it provides more freedom to optimize treatment modality for individual cases, it 
also complicates the decision-making process for orthopedic surgeons.  A rational attitude 
towards solving this issue is based on an assessment of the factors affecting bone healing (Figure 
4).  
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Figure 4: Diagram derived from Marsh and Li’s triad of interrelationships in the 
regenerative repair of fractures (Marsh & Li 1999). 
D.O.: Distraction osteogenesis. 
Support: gap filler and network for osteoprogenitor cells. 
 
 
Understanding which factor(s) are deficient in a given patient determines the criteria for selecting 
a therapeutic strategy.  If grafting is the answer, a good knowledge of the grafting agents 
available will guide the ultimate choice.  Table 1 summarizes the properties of grafting materials 
relevant to an appropriate selection.  In difficult cases, several contributing factors can be 
identified and a combination of therapies required.  For example, highly comminuted fractures in 
smokers may justify the use of cancellous allograft as an osteoconductive gap filler, mixed with a 
gel of demineralized bone matrix to provide growth factors.  In postirradiation patients, this 
combination can be further augmented by an autogenous bone marrow aspirate to increase the 
local population of mesenchymal stem cells (Redfern 2001).  Researchers are currently 
investigating alternative techniques to develop safe osteogenic grafts.  Mesenchymal cells have 
experimentally been harvested from recipients (via muscle or mesenchymal tissue biopsy, or 
bone marrow aspirate) and allowed to multiply ex-vivo (Kadiyala et al. 1997, Scaduto & 
Lieberman 1999).  DNAtransfer to these cultured cells can then occur via viral gene vectors (e.g. 
adenovirus, adeno-associated virus, and herpes virus) to stimulate their synthesis of growth 
factors such as BMP-2 (Evans & Robbins 1995).  This technology can be applied to bone 
formation, but also to stimulate the repair of cartilage, osteochondral defects, and tendons (Evans 
& Frisbie 2000; Imhoff & Martinek 2001).  
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As a simple answer rarely addresses a difficult problem, it is unlikely that one grafting agent will 
eventually be found to optimally resolve all orthopedic conditions where bone formation is 
challenged.  Instead, individual types of grafting materials are likely to improve in their 
biomechanical and biological performance as well as diversify and intertwine with each other to 
better answer specific issues.  A thorough and long-term evaluation of new biomaterials is 
indicated to verify their superiority over clinical controls and prevent side-effects such as 
transmission of pathogens or unpredictable resorption of the implant and newly formed bone.  
 
”Le primum non nocere” 
 
 
 
 
Table 1: Properties of grafting materials. 
 
Biomechanical 
Structural  
Nonstructural 
Biological properties 
Osteogenesis 
Osteoinduction 
Osteoconduction 
Composites 
 
Origin 
Synthetic 
Natural 
Bone-derived 
Others (e.g.: Coral) 
Sterilization 
Aseptic collection and processing 
Irradiation:  
Dose and temperature 
(Hamer et al. 1999) 
Chemical: 
Demineralization process 
(Scarborough et al. 1995)  
Ethylene oxide (veterinary only) 
Availability  
 
Presentation 
Massive 
Segments, blocks, or struts 
Chips 
Granules 
Particle size 
Particle size distribution 
Putty,  paste, gel 
Powder 
Fibers, flex (flexible grafts) 
 
Cost 
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5.  REVIEW OF THE LITERATURE 
 
 
5.1. LIMITATIONS OF ALLOGRAFTS  
 
5.1.1.  Processing and biomechanical properties: 
 
The most common use of cortical allografts in veterinary medicine has been in highly 
comminuted diaphyseal fractures (Figure 5) (Phillips et al. 1988).  Cortical bone grafts and 
implants have also been used to replace segments of bone after tumor excision (LaRue et al. 
1989), lengthen bones, and treat selected nonunions (Alexander 1983).   
 
 
 
In all of these cases, cortical allografts must retain biomechanical properties so that the repaired 
bone can withstand forces generated during weight bearing.  Biomechanical failure of cortical 
allografts has been documented (Mankin 1984; Berry et al. 1990; Wagner et al. 1994).  Use of 
fresh grafts ensures integrity of biomechanical properties, because the bone is unaltered 
structurally, but may generate an inflammatory response from the recipient (Friedlander 1983), 
especially in the event of major histocompatibility mismatches (Stevenson et al. 1991).  
Long-term preservation of bone has been developed to provide grafts at any time and in a variety 
of sizes. Multiple methods for sterilization and storage of cortical bone, including irradiation, 
ethylene oxide sterilization, freezing, and freeze-drying, have been described in people (Tomford 
et al. 1987; Ivory & Thomas 1993; Tomford & Mankin 1999).  Some of these techniques alter its 
biomechanical properties and make it unsuitable as a structural graft (Triantafyllou et al. 1975; 
Pelker et al. 1984; Johnson et al. 1987; Roe et al. 1988; Itoman & Nakamura 1991, Boyce et al. 
1999).  For example, gamma irradiation is the most popular sterilization technique of human 
bones harvested from cadavers.  A dose above 30 kGy is currently recommended to eradicate the 
? 
? 
Figure 5: Use of a cortical allogeneic 
bone segment to reconstruct an atrophic 
nonunion fracture in a canine femur. 
Arrows point at the host-graft junctions. 
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human immunodeficiency virus (HIV).  The adverse effects of such a high dose of radiation on 
bone graft are well established with respect to mechanical performance (Pelker & Friedlander 
1987).  A common method for banking cortical bone in veterinary medicine includes clean 
collection on cadavers and freezing after ethylene oxide sterilization.  This sterilization method is 
not recommended in human orthopedics because residual gas may remain within transplanted 
tissue and cause irritation (Norman-Taylor & Villar 1997).  Sterile collection and freezing under 
various conditions have been used in veterinary surgery to avoid side-effects of sterilization 
(Denny 1985; Johnson 1991).  Freezing does not seem to alter the biomechanical properties of 
cortical bone if surface hydration of the tissue is preserved (Bright 1983).  Addition of sodium 
chloride or lactated Ringer’s solution has been suggested to protect frozen bone from dehydration 
(Brinker et al. 1990; Laforest et al. 1991), but its effects on the biomechanical properties of 
frozen bone have not been evaluated.   
 
5.1.2.  Health and safety issues: 
 
The major disadvantage associated with sterile collection and freezing of bone involves 
transmission of pathogens.  Experiments have demonstrated the ability of fresh-frozen connective 
tissue allografts to transmit the feline leukemia retrovirus (Nemzek et al. 1994).  This risk is 
especially relevant in man, where diseases transmitted in bone allografts have included hepatitis 
B, hepatitis C, and acquired immnune deficiency syndrome (AIDS) (Tomford & Mankin 1999). 
Screening of donors and removal of blood products from bone allografts have helped reduce this 
problem.  According to the American Association of Tissue Banks (AATB) records, only two 
cases have been linked with documented transmission of AIDS since identification of the virus 
(American Association of Tissue Banks 1993; Gazdag et al. 1995).  Both cases involved 
transplantation of unprocessed, fresh-frozen allografts, with the last case dating back to 1985 
(Boyce et al. 1999).  However, any grafting material containing human tissue carries a potential 
for disease transmission.  The emergence of new pathogens, possibly more resistant to the 
sterilization techniques currently used prior to banking, has also raised public concern over the 
use of allografts. 
 
5.1.3. Shortage of supply: 
 
More than 15000 bone allografts are used every year in the United States alone (Tomford & 
Mankin 1999).  Most originate from cadavers, although they may occasionally be harvested from 
live donors.  For example, the most common source of corticocancellous allografts utilized in 
revision hip arthroplasties consist of femoral heads excised during a primary procedure.  Over 
800000 total hip replacements are performed annually worldwide, with approximately 150000 
occurring in the United States (Behairy & Jasty 1999).  Nonetheless, the supply may run short.  
For instance, the current harvest of approximately 1700 femoral heads per year in Scotland is 
expected not to meet the future demand for revision surgery of the hip (Galea et al. 1998).  This 
imbalance results from a couple of reasons: hip arthroplasty has become increasingly popular and 
is now applied to treat a greater variety of diseases (such as immune arthrites).  In these cases, the 
longevity of the implant is decreased and early revision is expected.  As the number of implants 
in place for more than 10 years increases, so does the number of revisions required: revision hip 
arthroplasties now represent about 10-20% of the case load of joint replacement surgeons 
(Bourne & Crawford 1999).  
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To palliate the limitations of autografts and allografts, a great deal of interest has focused on the 
development of bone substitutes, which may be broadly classified as osteoinductive or 
osteoconductive. 
 
 
5.2. OSTEOINDUCTIVE BONE GRAFT SUBSTITUTES 
 
Osteoinductive bone graft substitutes initiate and stimulate the differentiation of undifferentiated 
mesenchymal cells into osteoprogenitor cells (Urist et al. 1983; Forell & Straw 1993).  One 
strategy for developing a bone-inducing agent is to identify a single purified molecule, which 
could ultimately be confirmed as the agent of choice for clinical promotion of bone healing and 
regeneration (Anderson 1994).  Investigators have subsequently attempted to isolate, purify, 
partially sequence and then clone the cDNAs for all presently known bone morphogenetic 
proteins (BMP) (Wozney et al. 1988, Cook et al. 1994, Kirker-Head 1995).  At least 10 BMPs 
have been identified (Table 2) but two of these proteins have been particularly well described in 
man: recombinant BMP-2 and –7 (OP-1) (Mason & Renberg 2001). 
 
 
Table 2: Members of the Transforming Growth Factor Beta superfamily of genes.   
All Bone Morphogenetic Proteins belong to this group except BMP-1.  Members of each 
subfamily share 50-90% genetic-sequence homology, and 30-40% genetic-sequence homology 
with members of other subfamilies. Derived from Reddi 1994 and  Einhorn 1995. 
 
Transforming growth factor-beta 
subfamily 
Transforming growth factor-beta 1 
Transforming growth factor-beta 2 
Transforming growth factor-beta 3 
Transforming growth factor-beta 4 
(chicken) 
Transforming growth factor-beta 5 
(Xenopus) 
 
Inhibitin-activity subfamily 
Inhibitin-? 
Inhibitin-βA 
Inhibitin-βB 
Müllerian Inhibitin substance 
Bone morphogenetic subfamily 
Bone morphogenetic protein-2 (or bone 
morphogenetic protein-2A) 
Bone morphogenetic protein-3 (or 
Osteogenin) 
Bone morphogenetic protein-4 (or bone 
morphogenetic protein-2B) 
Bone morphogenetic protein-5 
Bone morphogenetic protein-6 (or Vgr 1) 
Bone morphogenetic protein-7 (or 
osteogenic protein-1 or OP-1) 
Bone morphogenetic protein-8 
(also known as OP-2) 
Bone morphogenetic protein-9 
Bone morphogenetic protein-10 
Decapentophegic gene (Drosophilia) 
Growth and differentiation factor-1 
Vegetal pole-derived gene (Xenopus) 
Drosophilia 60A 
 
 
However, there is increasing evidence that bone repair may be optimally enhanced by a 
combination of agents (Anderson 1994; Anderson et al. 1995).  Therefore, a second strategy for 
development of bone-inducing agents is to identify an optimal mixture of bone growth agents, 
either concocted from purified agents, or generated biologically as the product of a tissue or a 
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cultured cell.  The tissue most commonly used as a source of partially purified bone-inducing 
factors has been decalcified bone (Table 3) (Bolander & Balian 1986; Urist et al. 1987; Hopp et 
al. 1989; Johnson EE et al. 1992).  Demineralized bone matrix (DBM) is commercially available 
as several preparations, differing in the processing technique and composition.  For example, 
carriers for demineralized bone matrix include glycerol, pluronic-F127 copolymer, porcine 
gelatin, hyaluronic acid, corticocancellous chips, collagen, and a mixture of calcium sulfate and 
methylcellulose (Abjornson Manitta 2001).  Manufacturers claim that this variation in 
formulation may affect the osteoinductive properties of the final product (Russel 2001). 
 
Table 3: Examples of osteoinductive agents under consideration, or currently used for 
clinical applications. 
 
Product name Content Comments 
BONE DERIVED 
AAA Bone Human chemosterilized 
autolized antigen extracted 
bone 
Described by Urist in 1981 
Structural and delivery 
system for hBMP in 
nonunions (Johnson 2000) 
Grafton (Osteotech Inc., 
USA) previous DBM gel 
human DBM, available 
since 1991 
Glycerol as a carrier 
Gel, putty, flex, fibers and 
crunch (fibers and cubes) 
Osteofil (Sofamor Danek 
Group Inc., USA) 
human DBM: 24% + 17% 
porcine gelatin as carrier, 
in aqueous solution 
Moldable, hardens to a 
rubber-like consistency at 
body temperature. 
Lack of clinical data (Ladd 
1999) 
DynaGraft (GenSci, 
Canada) 
human DBM Lack of clinical data (Ladd 
1999) 
Opteform (Exactech Inc, 
USA) 
Compacted 
corticocancellous human 
bone chips and human 
DBM+porcine 
gelatin+water 
Moldable putty 
Lack of clinical data (Ladd 
1999) 
Canine DBM (Veterinary 
Transplant Services, USA) 
Demineralized bone 
matrix 
Cortical powder, with or 
without cancellous chips 
Veterinary use 
COMPOSITES 
rhBMP-2 (Genetics 
Institute, USA) 
Synthetic BMP with an 
absorbable collagen 
sponge as a carrier 
Undergoing clinical trials: 
Tibial callotasis (Eyres 
2001) 
rh-BMP-7 (Ceative 
biomolecules, USA) 
Synthetic BMP with 
collagen 
Undergoing clinical trials: 
Osseous defects (Geesink 
1999) 
Osteoconductive grafts (see table below) mixed with demineralized bone matrix or 
autogenous bone marrow 
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The major limitation to the clinical use of such preparations is the very low concentration of bone 
morphogenetic proteins in whole bone (Figure 6): about 1 mg of pure BMP can be extracted from 
1 kg of bovine bone (Wozney 1993).  This considerably increases the cost of extracting a native 
bone-inducing therapeutic agent and does not eliminate the risk of disease transmission. 
 
 
Organic
Mineral
Mineral phase 70%
Hydroxyapatite 95%
Magnesium
Sodium, Potassium
Fluoride, Chloride
Organic phase 30%
Matrix 98%
Collagen 95%
Noncollagenous proteins 5%
(BMP, TGFβ: 2% NCP)
Cells 2%
Osteoblasts
Osteocytes
Osteoclasts
 
 
Figure 6:  Composition of bone. 
 
Extraction of a natural osteoinductive agent from cultured cells may be a less expensive 
alternative for the unlimited production of a bone-inducing agent.  A Bone-inducing agent (BIA) 
extracted from a cultured human osteosarcoma cell line (Saos-2) and has been found highly 
osteoinductive when implanted in the skeletal muscle of athymic mice (Anderson et al. 1992).  
Ten milligrams of BIA extracted from Saos-2 cells (mixed with bovine collagen) promotes early 
osseous union of an internally fixed diaphyseal femoral nonunion in immunocompetent rats 
(Hunt et al. 1993). In this study, an equal amount of bovine collagen was mixed to the BIA to act 
as a slow-release protein delivery system.  Osteoinductive agents are always combined with a 
carrier, which usually consists of an osteoconductive biomaterial.    
 
 
5.3.  OSTEOCONDUCTIVE BONE GRAFT SUBSTITUTES 
 
Osteoconductive materials provide a passive scaffold onto which osteoprogenitor cells can lay 
new bone. Osteoconductive agents (Table 4) include ceramics, collagen, porous metals, 
polyglycolic and polylactic acid polymers, and bioactive glasses (Cornell 1999). They are usually 
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too brittle to bridge large bone defects but are used as nonstructural fillers in maxillofacial, 
neurologic and orthopedic surgery. They can also function as carriers for growth factors and 
antibiotics, and may present as blocks, fibers, granules, powders, gels, and sprays, depending on 
the application.  The properties of osteoconductive grafts will therefore be determined by their 
physical presentation as well as other factors, such as chemical composition, processing, 
granulometry, and interconnective porosity (Table 1).  
 
Table 4: Some commercial forms of osteoconductive biomaterials. 
 
Product name Content Comments 
BONE DERIVED 
Kiel bone (Surgical 
University Clinic of Kiel, 
Germany) 
Bovine bone deproteinized 
by hydrogen peroxide and 
defatted with ether 
Historical use in 1960s 
Opteform Compacted corticocancellous 
bone chips 
Contains gelatin and water 
Bio-oss Sintered bovine bone  
Oxbone Sintered bovine bone  
Endobon (Merck KGaA, 
Germany) 
Sintered bovine cancellous  Blocks 
Use approved in Europe, not 
USA. 
Surgibone (Unilab Inc, 
UK) 
Processed mature bovine 
bones 
Contain mainly HA and  
20-29% proteins 
Lubboc (Transphyto, 
France) 
Processed young bovine 
cancellous bone 
Blocks, plates, fragments 
Pyrost  Sintered bovine bone Contains 93% HA, 
stronger than Collapat. 
Potential structural graft 
Osteoplant (BioTeck, Italy) Equine irradiated 
demineralized bone matrix 
Blocks, granules, flex 
Cancellous or cortical origin 
Canine bone allograft 
(Veterinary Transplant 
Services, USA) 
Cancellous or cortical bone Whole bones, sections, 
blocks, wedges, struts, 
cancellous chips 
Veterinary use 
Osteomin (Pacific Coast 
Tissue Bank, LA, USA) 
human bone ash: Microporous 
HA 
Particulate  
Banked human allograft  Cancellous, cortical, 
corticocancellous, or 
osteochondral bone 
Sections, blocks, wedges, 
struts, chips, particulate, 
powder 
Properties vary with 
processing 
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HYDROXYAPATITE 
Biocoral (Inoteb, France) Natural mineral skeletons of 
scleractinian corals 
Manufacturer recommends 
augmentation with 
autogenous bone marrow 
ProOsteon (Interpore Int., 
USA) 
previous name: Replam 
Hydroxyapatite-Porites or 
RHAP 
Replaniform coralline 
macroporous HA 
200: derived from Porites 
porites (pore size 190-230 µm) 
500: derived from Porites 
Goniopora (larger pores) 
R: Resorbable  
Particulate or block 
Brittle. Radiopacity impedes 
assessment of healing. 
Slow resorption 
R-form produced by 
premature termination of the 
thermochemical exchange  
Calcitite (Calcitek, USA) Dense crystalline HA Granules, diameter:  
400-800µm 
Periograf (Cooke-Waite 
Laboratories, USA) 
Dense crystalline HA  
Ceros 80 (Straumann Ltd, 
UK) 
Dense polycrystalline HA Particules with very little to 
no resorption in vivo 
Osprovit (Cerasiv, 
Germany) 
Porous HA  (pore size:  
200-600 µm)  
Oral and maxillofacial 
surgery 
OrthoMatrix HA-
SYSTEM 
Includes HA-500, HA-1000, 
and HA-2000, with particle 
diameter ranging from 240 to 
2000 µm 
Particulate, oral, and 
craniofacial surgery 
Friabone, Algipore and 
Frialit (Friedrichsfeld, 
Germany) 
HA  
Biosorb HA  
Cerapatite (Ceraver Osteal, 
France) 
HA  
OsteoGraf (CeraMed, USA) Crystalline HA AR or P: dense 
N or M: microporous 
OsteoGen (Impladent, 
USA) 
Crystalline HA Particulate 
TRICALCIUM PHOSPHATE AND CEMENTS 
Ceros 82 β-TCP, porosity varies to 
adjust resorption between 6 
and 12 months 
Lower compressive strength 
than Ceros 80 
Calciresorb (Ceraver 
Osteal, France) 
Porous TCP Periodontal applications 
Synthograf (Miter, USA) Small size and dense TCP Periodontal applications 
Augmen (Miter, USA) Larger size and dense TCP Periodontal applications 
BoneSource (Howmedica, 
USA) 
Calcium phosphate Putty, maxillofacial surgery 
Alpha BSM Calcium phosphate Moldable putty, 
maxillofacial surgery 
Orthocomp Calcium phosphate  Cement 
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Norian Skeletal Repair 
System (SRS) (Norian 
Corp., USA), formely 
Superbone 
Powdered calcium phosphate 
and calcium carbonate mixed 
with a solution of calcium 
phosphate prior to use 
Injectable cement, 
augmentation of fracture 
repair. Hardens in 10 mn, 
generating negligible heat. 
Support in compression, 
weak in torsion and shear 
E-TEX α-BSM (E-TEX, 
USA) 
Calcium phosphate Injectable cement, dental 
applications as a void filler 
Vitagraft (Orthovita, USA) Calcium phosphate  Moldable cement 
OSTEOCONDUCTIVE COMPOSITES 
Triosite (Zimmer Europe 
Ltd, UK) 
60% HA, 40% TCP Also called MBCP 
(macroporous biphasic 
calcium phosphate) or BCP 
Ostilit (Stryker Howmedica 
Osteonics, UK) 
80% TCP, 20% HA, not 
macroporous 
Granules and blocks 
nonstructural graft 
BoneSave (Stryker 
Howmedica Osteonics, UK) 
80% TCP, 20% HA, pore size: 
400-600µm 
Granules, stronger than 
Ostilit, for use as a void 
filler and in impaction 
grafting 
Healos HA coated bovine collagen Sponge 
Collagraft (Zimmer Inc, 
USA), formerly Colhap 
Bovine collagen, 60%HA and 
40% TCP, pore size: 300-
700µm 
Granules and strips 
Requires augmentation with 
aspirated marrow 
Collapat (Ostobalag, 
Switzerland) 
Collagen + crystals (<20µm 
diameter) of 90% HA and 
10%TCP 
Collagen: commercial 
preparation of pig skin 
(Pentapharm) Nonstructural 
applications 
Cerapatite-collagen 
(Ceraver Osteal, France) 
HA-Collagen Nonresorbable 
Calciresorb-collagen 
(Ceraver Osteal, France) 
TCP-Collagen Resorbable 
Biofibre (Norian Corp., 
USA) 
Spherulite formulation of 
calcium phosphate crystals 
mixed with collagen 
 
TITANIUM CYLINBERS AND FIBER METAL RODS 
Modular Segmental Spinal 
Instrumentation or MOSS 
(Biedermann Motech 
GmbH, Germany) 
Titanium-mesh cylinder Vertebral substitute 
BIOACTIVE GLASSES (see table below) 
CARBON FIBERS 
OTHERS 
Osteoset (Wright Bio-
Orthopedics, USA) 
Calcium sulfate Pellets, resorbed in 6-8 
weeks, no structural support 
HTR synthetic bone 
(Bioplant, USA) 
Polymer: Microporous 
composite of PMMA, calcium 
hydroxide, 
polyhydroxylethylmethacrylate 
HTR: hard tissue 
replacement 
Seemed to hinder healing 
Historical use 
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5.3.1. Ceramics 
 
Synthetic hydroxyapatite, tricalcium phosphate, and combinations of the two are the prevailing 
bone graft substitutes (Behairy & Jasty 1999).  The mineral phase of bone represents 
approximately 60% to 70% of its dry weight (Figure 6) and consists of carbonated, calcium 
phosphate apatite (Posner 1985).  Ideally, a bone graft substitute would have a similar mineral 
composition and structure.  This was one of the reasons why calcium phosphate substrates 
supplanted calcium sulfate compounds, such as plaster of Paris (Tay et al. 1999).  Klawitter 
(Klawitter & Hulbert 1971)  established the need for ceramics to present pores of at least 100 µm 
to allow bone ingrowth.  Porous hydroxyapatite (HA) and tricalcium phosphate (TCP) are 
typically produced by isostatic compaction of calcium phosphate powder with naphtalene. The 
naphtalene is subsequently removed, creating a porous structure that is then sintered (Cornell 
1999).  Biodegradation of TCP and HA relies on cell-mediated mechanisms and dissolution, both 
of which are related to implant surface area (Holmes 1994).  Porosity, as well as particle size, will 
therefore affect the degradation rate of the compound and the biomechanical properties of the 
implant.  Thus, it is crucial to differentiate between dense and macroporous forms of 
hydroxyapatite (Burwell 1994).  The latter has a higher resorption rate but is mechanically 
weaker.  Because TCP dissolves more rapidly than HA (Tay et al. 1999), it is also possible to 
adjust the resorption kinetics of composite materials by varying the ratios of hydroxyapatite and 
tricalcium phosphate (Behairy & Jasty 1999).  Although TCP/HA mixtures have been evaluated 
in bone defects (Gatti et al. 1990; Frayssinet et al. 1993), further studies are needed to determine 
the ideal mixture to be used as an impacted, idealised morselized aggregate in revision hip 
arthroplasty. 
 
5.3.2.  Bioactive glasses 
 
A potential advantage of bioactive glass over HA and TCP is a superior biomechanical strength, 
while simultaneously retaining the ability to form a strong chemical bond with bone. According 
to Yamamuro, glass ceramics containing apatite and wollastonite (AW-BC) synthesized since 
1980 at Kyoto were stronger than human cortical bone and bonded with living bone within 8-12 
weeks (Yamamuro et al. 1987; Kokubo 1993).  This material was successfully used as vertebral 
prosthesis following spinal tumor removal in four patients.  
Bioactive glasses contain SiO2 as a network former, which results in slow and incomplete 
resorption. Controlled release glasses (CRG) are inorganic polymers based on phosphates of 
sodium and calcium converted into a glassy form.  They differ from other traditional bioactive 
glasses (Table 5) (Fetner et al. 1994; Heikkilä et al. 1995; Hench 1998; Ikeda et al. 1999) in that 
they do not contain SiO2.  When exposed to tissue fluids, traditional bioactive glasses form a 
bonding layer of biological hydroxy-carbonate-apatite with an underlying layer of silica gel 
(Hench & Parschall 1973; Wilson et al. 1993), while CRGs dissolve completely in water and 
create an acidic environment (Gilchrist et al. 1991).   
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Table 5: Examples of bioactive glasses available commercially. 
 
Bioglass (American 
Biomaterials Corp., USA) 
Bioactive glass, 45% silica, 
24.% calcium oxide, 24.5% 
disodium oxide, 6% 
pyrophosphate 
Original glass developed by 
Larry Hench in the 1970s 
Consil (Xeipon Ltd, UK) Bioactive glass Particulate bioglass for 
veterinary use  
NovaBone (American 
Biomaterials Corp., USA) 
Bioactive glass Reconstructive procedures 
and void filler, resorption 
rate? Limited clinical data 
Biogran (Orthovita, USA) Bioactive glass, narrow 
particle size range: 300-355 
µm 
Void filler, dentistry 
Superior osteoconduction? 
PerioGlass (Block Drug 
Co., USA) 
Bioactive glass, particle size 
range: 90-710 µm 
Void filler, dentistry 
Ceravital (E.Pfeil & H. 
Brömer, Germany) 
Group of glasses and glass 
ceramics of various 
compositions 
Experimental use 
nonstructural grafts for ear 
surgery.  
 
 
Controlled release glasses are biocompatible and have been shown to allow rapid growth of 
viable bone, in a manner similar to autografts (Burnie & Gilchrist 1983; Paul et al. 1983; Burnie 
et al. 1991).  Blocks of bioactive glass alone have been found to be too brittle for use in structural 
reconstructions (Damien & Parsons 1991; Virolainen et al. 1997).  Likewise, uncompacted 
aggregates of a new controlled release glass, Corglaes®, have been shown to be weaker than 
morselized bone (Brewster et al. 1999).  However, correcting particle size distribution of 
morselized allografts produced for clinical use in revision hip arthroplasty with small particles of 
Corglaes® ("idealizing the graft") improved their biomechanical properties (Brewster et al. 1999).  
CRGs may therefore be considered as potential graft substitutes in revision hip arthroplasty, 
although the biological properties of impacted aggregates of morselized CRGs warrant further 
investigation. 
 
 
5.4. IMPACTION GRAFTING FOR REVISION HIP ARTHROPLASTY  
 
Numerous techniques have been described for revision hip arthroplasty in man, but the outcome 
still remains less favorable than that of primary arthroplasties (Brewster et al. 1999, Robinson et 
al. 1999).  The endosteal surface surrounding loose femoral stems is often smooth and 
compromises adequate micro-interlock of the cement with the host (Dohmae et al. 1988; Bourne 
& Crawford 1999).  The loss of bone stock induced by wear particles may also be such that 
mechanical containment of the implant and cement mantel is difficult to achieve (Berry 1998).  
One technique to overcome these problems consists of packing morselized corticocancellous 
allograft around a cemented implant (Figure 7).  Impaction grafting in revision hip arthroplasty 
was first reported for acetabular reconstruction by Sloof in 1984, and was later described for 
revision of the femoral component by Simon et al. (1991).   
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Figure 7: Postoperative radiographs of a patient who had undergone 
bilateral impaction grafting hip arthroplasty.  Note the decreased 
radiopacity of both proximal femora.  On each side, the femoral cortex is 
reinforced with a metallic mesh and cerclage wires prior to impacting 
corticocancellous allograft in the canal.  The femoral prosthesis is a 
collarless polished tapered stem (Exeter) (Courtesy of D Dunlop). 
 
 
Early clinical results were encouraging (Gie et al. 1993), but recent studies have reported a high 
incidence of subsidence and fracture of the femoral stem (Eldridge et al. 1997; Leopold et al. 
1999; Knight & Helming 2000).  Further evaluation of the mechanical and biological behavior of 
impacted morselized grafts seems therefore warranted.   
Nevertheless, the use of impaction grafting remains particularly appealing for revision 
arthroplasty in patients with severe osteopenia of the proximal femur (Meding et al. 1997).  
Potential advantages of this technique include increased interdigitation of the cement with the 
graft and augmentation of proximal femoral bone stock (Schreurs et al. 1994; Nelissen et al. 
1995).  However, safety concerns and limited supplies have stimulated the search for synthetic 
agents to augment or replace allografts.  Correcting the particle size distribution of morselized 
allografts produced for clinical use with small particles of bone or synthetic material ("idealising 
the graft") has also been shown to improve their biomechanical properties (Brewster  et al. 1999).  
These findings correlate with the particulate aggregate theory, according to which well-graded 
grafts, with a particle size distribution approaching the ideal logarithmic grading line, resist shear 
strains better than aggregates of more uniform size.  However, the resultant increase in cohesion 
may affect neovascularization and incorporation of the graft. 
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5.5. ANIMAL MODELS 
 
Osteoinductive properties of grafts are typically tested in sites void of osteoprogenitor cells, so 
that any new bone will result from the differentiation and proliferation of undifferentiated 
mesenchymal cells. Muscle and subcutaneous tissues are the most common implantation sites for 
osteoinductive bioassays. The latissimus dorsi muscle is an attractive site of implantation because 
it is easy to expose and offers a large section of muscle of similar thickness.  Bone formation is 
usually detected within two weeks after heterotopic implantation of an osteoinductive agent in 
athymic mice.  In monkeys and dogs, osteoinductive bioassays are usually prolonged to six to 
eight weeks (Sato & Urist 1985; Miyamoto et al. 1993; Ripamonti 1993) to compensate for their 
slower metabolic rate compared to rodents (Sato & Urist 1985; Cook et al. 1994). 
Osteoproductive properties in general, and osteoconduction in particular, are evaluated in 
orthotopic sites. Unicortical bone defects are well-established models for evaluation of the 
biological properties of grafting materials.  Unicortical defects have several advantages over non-
union models: they do not require internal fixation and allow the evaluation of several local 
growth factors in the same animal. One of their limitations is related to the size of the defect and 
the risk of fracture secondary to a stress rising effect. Diaphyseal defects involving 20% of the 
diameter of the bone decrease the torsional strength by 34% (Edgerton et al. 1990).  Whereas 
previous studies describe the use of diaphyseal unicortical defects measuring up to 9 mm in 
diameter in sheep (Frayssinet et al. 1993), the metaphysis of long bones can accommodate larger 
defects (Sartoris et al. 1986; Sauk & Van Kampen 1991). The other advantage of metaphyseal 
defects over diaphyseal defects is related to the balance between osteogenesis and biodegradation 
of grafting materials in cancellous bone.  Lu et al. (1998) recently compared tissue reactions to 
calcium phosphate ceramics among cancellous, cortical, and medullar implantation sites in 
rabbits: medullar sites exhibited stronger immune response and faster biomaterial degradation, 
whereas osteoproduction was increased within cortical sites.   Cancellous sites had intermediate 
activities and are therefore recommended as models for evaluation of the properties of 
biomaterials.  Another limitation of unicortical defect models relates to the lack of biomechanical 
loading, which is especially relevant if the biomaterials tested are being considered for use as 
structural grafts.  
Orthotopic evaluation of osteoproductive agents are typically performed in critical-sized 
diaphyseal defects or in fracture-healing models (Bostrom et al. 1999).  These models simulate 
clinical applications better than unicortical defect models but have several pitfalls.  The first type 
of models, based on the creation of defects that do not heal without implantation of a graft, is 
designed to simulate nonunions. However, it fails to mimic the clinical situtation encountered in 
nonunions, because it is the size of the defect, not a compromised healing environment that 
prevents healing.  These models therefore more suited to reproduce massive bone defects, such as 
those resulting from excision of a neoplasm.  In contrast to critical-sized defects, fracture-healing 
models rely on fracture or osteotomies that heal regardless of treatment.  The goal is then to show 
that an otherwise normal healing process (as opposed to a compromised healing process) can be 
augmented and possibly accelerated by the therapy tested.  This is often challenging and the 
biologic and biomechanical variability among different models is such that comparison of results 
between studies is difficult.  Compared with unicortical defect models, fracture-healing and 
critical-sized defect models are more invasive and technically more difficult to use. One of their 
main limitations is that only one treatment can be evaluated per animal.  Evaluation of several 
treatments and variations between individuals increase the number of animals required to reach 
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statistical significance, as compared with a model where several implantation sites can be created 
in each animal.                                                                                         
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6.  AIMS OF THE STUDY 
 
 
The general intent of this work was to develop a sound methodology  to evaluate the properties of 
three types of grafting biomaterials with regard to specific clinical applications and to provide 
insight into the different grafting stategies to enhance bone formation.  
 
Specific goals were as follows: 
 
Study I: 
• To evaluate the biomechanical properties of allograft frozen in saline for one year, in 
bending and torsion. 
• To compare these properties to matched bones stored in dry containers 
  
Study II: 
• To test the osteoinductive properties of a bone inducing agent (BIA) in higher vertebrates 
• To evaluate the biological properties of the agent in orthotopic sites 
• To compare the osteoproductive properties of BIA with negative (empty defect) and 
positive controls (autogenous cancellous graft)  
 
 
Study III: 
• To develop and evaluate a model simulating the environment encountered in revision hip 
arthroplasty. 
• To study the biological properties of several impacted aggregates of large particles in the 
same animal (higher vertebrate) 
 
Study IV:  
• To determine the in vivo dissolution rate of a new, silicate-free, idealized, morselized 
bioactive glass 
• To evaluate the osteoproductive properties of the agent, alone or combined with allograft 
 
Study V: 
• To evaluate the effect of idealizing particle size distribution of impacted aggregates on 
their vascularization and incorporation. 
• To evaluate the osteoproductive properties of two mixtures of impacted, idealised, 
morselized tricalcium phosphate and hydroxyapatite. 
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7.  MATERIALS AND METHODS 
 
 
7.1.  GRAFTING MATERIALS: 
 
7.1.1.  Corticocancellous bone (Study I) 
 
a.  Specimen collection   
A total of eleven pairs of metacarpal bones, ten pairs of metatarsal bones, and seven pairs of ribs 
were cleanly collected from four healthy large mixed breed adult dogs, euthanized after surgical 
teaching laboratory experiments.  Metacarpal and metatarsal bones were collected to obtain a 
maximal number of paired long bones and enable better use of donors.  Ribs were included as 
another source of corticocancellous bone.  All soft tissue was removed by sharp dissection.  
Epiphyses and cancellous bone were left intact. High-resolution radiographic views (Faxitron 
Series Model No.43805-N, Hewlett Packard Corp., McMinnville, OR, USA) using nonscreen 
film (Kodak X-OMAT TL Film, Eastman Kodak Co., Rochester, NY, USA) were obtained for all 
specimens.  
 
b.  Storage   
The bones were individually packaged in transparent polyethylene containers (Whirl-pack bags, 9 
x 4 1/2 inches, Nasco, Fort Atkinson, WI., USA) and allotted to two groups.  One bone of each 
pair (randomly assigned) was immersed in a polyethylene bag containing 200 ml of normal saline 
solution (NSS).  The contralateral bone was stored in a polyethylene pack without NSS (Figure 
8).  
 
 
 
Each container was labeled and stored in a conventional freezer at a constant temperature -20ºC 
for one year.  All frozen specimens were allowed to thaw within their wrappers at 20 to 22ºC, 
prior to biomechanical testing. 
 
 
7.1.2. Bone-inducing agent (Study II) 
 
The Saos-2 human osteosarcoma cell line was initially propagated in vitro from osteosarcoma 
tissue of an 11-year-old Caucasian female (Fogh & Trempe 1975).  The bone-inducing agent 
Figure 8: Storage of pairs of  ribs, 
metacarpal and metatarsal bones. 
One bone is immersed in 200 ml of 
normal saline solution, while the 
contralateral bone is stored in a dry 
polyethylene pack. 
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(BIA) was extracted after resuspension of freeze-dried, acetone-defatted Saos-2 cells in 4M 
guanidinium hydrochloride (Hunt et al. 1993).  The extract was then partially purified by gel 
filtration chromatography to obtain a 10-50 kDa fraction of BIA.  Bioassays were performed in 
mice prior to implantation in dogs (see Bioassays for osteoinduction). 
 
BIA implants were then prepared for use in dogs by placing 10 mg of BIA and an equal amount 
of pure bovine collagen (Vitrogen, Collagen Corp., USA) into a #4 gelatin capsule (Eli Lilly and 
Co., Indianapolis, IN, USA).  The implants were gas-sterilized in ethylene oxide and stored in 
plastic containers, at -700C, until used.  For comparison, control implants were prepared, 
consisting of 20 mg of pure bovine collagen in a #4 gelatin capsule and a #4 gelatin capsule 
alone.  The last type of implant was fresh autogenous cancellous bone, collected at the time of the 
operation, and packed into a #4 gelatin capsule (Figure 9). 
 
 
 
 
7.1.3. Morselized corticocancellous allograft (Studies III, IV, and V) 
 
Corticocancellous bone was aseptically collected from the femoral and humeral heads as well as 
distal femora of two adult sheep euthanized as part of an experiment unrelated to orthopedics.  
Bones were morsellised under aseptic conditions with a bone mill (Aesculap), using the 3- or 6- 
mm grater (Figure 10).  
 
 
 
 
Figure 10: Aesculap bone mills - Left: 6-mm and 3-mm graters. Right: mounted bone mill. 
Figure 9: Implants used for evaluation of a BIA, 
from left to right:  
• 10 mg of BIA and 10 mg of bovine collagen 
• Fresh autogenous cancellous graft 
• Empty capsule 
• 20 mg of bovine collagen 
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A well-graded specimen of allograft (AlloG) was prepared by mixing 2/3 of small and 1/3 of 
large particles (Figure 11) by weight. 
 
 
 
 
 
The bone was stored in sterile double-layer polyethylene wrappings at a temperature of –700C. A 
sample of the mixture was submitted for bacterial culture. 
 
7.1.4. Bioactive glass (Studies III and IV) 
 
Corglaes® (Giltech Ltd., Ayr, UK) is a family of bioactive glasses containing pyrophosphate 
(P2O5) rather than silica dioxide (SiO2) as a network former.  These glasses comprise 42-49 
mole% of P2O5, the remainder as 10-40 mole% of CaO and Na2O.  Test material was prepared by 
premixing and melting phosphates of sodium and calcium at 11000C until stable.  The melted 
glass was cast onto steel and annealed to remove stress.  The chemical composition of the 
material was adjusted based on previous studies (Burnie & Guilchrist 1991), to produce a glass 
wthat as a 4.0-mm-diameter granule, was estimated to dissolve in 12-14 weeks, in a bone defect.  
The annealed glass was then crushed, fractionated through a series of eight vibrating sieves, and 
sterilized by irradiation.  Glass particles were provided in eight size ranges (Figure 12):  
 
 
Figure 11: Preparation 
of an idealized mixture 
of morselized allograft. 
Distal femora, femoral 
and humeral heads (Top)
were collected 
aseptically and 
morselzsed into large 
(small arrow) and small 
particles (Bottom right) 
 
? 
? 
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Particle size ranges (mm) 0.3-0.5 0.5-0.71 0.71-1 1-1.4 1.4-2 2-2.8 2.8-4 4-5.6 
Corresponding sieve size (µ)  300 500 710 1000 1400 2000 2800 4000 
 
 
 
 
 
Because particles were somewhat irregular in shape, the modified logarithmic line rather than the 
original Fuller’s curve was used to idealize the mixture (Brewster et al. 1999).  Based on this 
curve, logarithmic particle size ranges were determined such that an idealized aggregate of 
Corglaes® could be prepared by mixing equal amounts (in weight) of each particle size range.  
Two groups contained allograft and Corglaes®: 
The first consisted of allograft idealized with bioactive glass particles.  The particle size 
distribution of allograft morselized with the 6-mm diameter bone mill used in our study has 
previously been described (Brewster et al. 1999).  Based on this data, the amount of bioactive 
glass to add to each sieve size was calculated to equalize the weight of the mixture in each 
particle size range. The particle size distribution of the final specimen therefore matched the 
theoretical optimum.  This mixture of bone idealized with Corglaes® contained 20-25% by 
volume of bioactive glass particles. 
The second consisted of 50% (by volume) idealized, morselized allograft and 50% idealized 
bioactive glass.  
 
Phase I therefore included six treatment groups: 
• Empty defect (negative control) 
• Fresh autogenous corticocancellous bone (positive control) 
• Idealized corticocancellous allograft (clinical control) 
• BG 1: Allograft idealized with particles of Corglaes® 
• BG 2: 50/50 mixture of idealized allograft/idealized Corglaes® 
• BG 3: Idealized Corglaes® 
Anaerobic and aerobic cultures were obtained for all implants prior to storage at –700C. 
 
7.1.5.  Tricalcium phosphate – hydroxyapatite (Studies III and V) 
 
Calcium phosphate ceramic granules were sterilized by γ-irradiation (BoneSave™; Stryker-
Howmedica). The pore size was 400-600 µm, with an interconnectivity pore size of <100 µm and 
Figure 12: Particles of bioactive glass 
were provided in eight size ranges so 
that an idealized mixture could be 
prepared by mixing equal weights of 
each size range. Corticocancellous 
bone was morselized with a 3- and a 6- 
mm grater to produce small and large 
particles. 
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a porosity of 50%. Two types of granules were used, differing by ratio of tricalcium phosphate 
(TCP) to hydroxyapatite (HA). The first granules, containing 80% TCP and 20% HA, were 
serially sieved to obtain a range of eight particle sizes (mm):  
 
 
0.3–0.5 
 
 
0.5-0.7 
 
0.7-1.0 
 
1.0-1.4 
 
1.4–2.0 
 
2.0-2.8 
 
2.8–4.0 
 
4.0-5.6 
 
 
The particle size increments increased logarithmically. An equal weight of each size band 
produced an idealized stock mixture of 80%TCP-20%HA particles. The second type of granules 
was treated in an identical manner to produce an idealized stock mixture of 20%TCP-80%HA 
particles (Figure 13).  
 
A fourth stock mixture was manufactured from 20%TCP-80%HA particles of three size bands 
only (< 0.5 mm, 1.0-2.0 mm and 2.0-4.0 mm) in a 1:2:1 ratio by weight.  This mixture was only 
approximately idealized (Figure 13). 
 
 
 
 
 
Using the four stock mixtures, four treatments were manufactured for implantation into bone 
defects in Phase II of the study: 
• The positive control consisted of morselized, idealized corticocancellous allograft alone.  
• A second group included equal volumes of idealized “TCP80-HA20” particles and idealized 
allograft. 
• Equal volumes of idealized “HA80-TCP20” particles and idealised allograft were mixed to 
form the third treatment group. 
• The last group consisted of idealized corticocancellous bone mixed with an equal volume of 
80%HA-20%TCP particles of three sizes only, simulating a clinically expedient method of 
graft preparation. 
 
 
Figure 13: Preparation of 4 stock 
mixtures, from top to bottom: 
• Particles of TCP 80-HA 20 in 8 
size ranges (BoneSave™) 
• Particles of HA80-TCP20 in 8 
size ranges 
• Particles of HA80-TCP20 in 3 
sizes to approximate idealization 
• Idealized corticocancellous 
allograft 
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7.2.  IN VITRO STUDIES: BIOMECHANICAL TESTS (Study I) 
 
7.2.1.  Four-point bending to failure 
 
Seven pairs of ribs, 5 pairs of metacarpal bones, and 5 pairs of metatarsal bones were loaded in 
four-point bending to failure.  Metacarpal and metatarsal bones were placed between four 
supports, with the plantar aspect of the bone facing upward (Figure 14).  Ribs were placed with 
the external side facing upward.  A bending moment was applied at a rate of 0.5 mm/s, using a 
modified servohydraulic test frame (MTS Systems Corp., Minneapolis, MN, USA) and a 
controller (Interlaken Inc., Minneapolis, MN, USA).  
 
 
7.2.2. Torsion tests: 
 
Five pairs of metatarsal and 6 pairs of metacarpal bones were tested to failure in torsion (Figure 
15).  Ribs could not be mounted on the torque frame because of their shape, and thus, were not 
tested in torsion.   
 
 
 
Figure 14: Modified servohydraulic frame used for four-
point bending tests.  
 
The distance between one loading point and the 
corresponding support (d) was used to calculate the bending 
moment (M, Newton.meter [N.m]): 
         F (N) 
 M (N.m) =  -------- x d (m) = 0.0065 F, 
     2 
where F= Force applied (Newtons) 
 
Figure 15: Testing in torsion to failure. 
 
A 1.1-mm-diameter Kirschner wire was placed through the 
distal end of each bone before mounting in Wood's metal 
(Cerro-Bend alloy, Satterlee Co., Minneapolis, MN, USA), to 
prevent slippage between the bone and the fixture during 
testing.  The bones were potted in Wood's metal heated above 
its melting point of 70ºC (Rand 1981).  The specimens were 
potted so that the distance of bone exposed between the 
supports was constant and equal to 35 mm.  Specimens were 
then placed in fixtures attached directly to the servohydraulic 
torque frame (MTS Systems Corp., Minneapolis, MN, USA).  
The proximal end of each bone was in the upper fixture, and 
the distal end  in the bottom fixture.  Bones were tested to 
failure in torsion at a rate of 30 degrees/s. 
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7.2.3. Data analysis: 
 
Bending and torsion forces were directly sampled using an analog to digital converter. Load-
deformation curves were analyzed using a scientific graph system (Sigmaplot Software, Jandel 
Scientific Graph System, Corte Madera, CA, USA).  The failure point was assumed to be the 
point of maximal torque for torsion testing, and the point of maximal bending moment for 
bending tests.  The yield point was the intersection point between the load-displacement curve 
and a straight line parallel to and 0.1 mm off the regression line of the load-displacement curve.    
 
 
7.3.  IN VIVO STUDIES: ANIMAL MODELS (Studies II to V) 
 
7.3.1.  Animals and surgical procedures: 
 
a. Bioassays for osteoinduction  (Study II) 
In mice: 
To validate the extract prior to use in dogs, 3 mgs of BIA mixed with an equal amount of pure 
bovine collagen were placed in gelatin capsules and implanted in the Latissimus dorsi muscles of 
athymic Nu/Nu mice.  The sites of implantation were excised two weeks later, fixed for 24-48 
hours in 10% phosphate-buffered formalin, and embedded in paraffin.  Five-µm-thick sections 
were stained with haematoxylin and eosin, without decalcification.  Sections were then evaluated 
with a Zeiss EM 10-A electron microscope for evidence of bone formation.   
 
In dogs: 
Five male Beagles with normal thoracic radiographs were sedated with intramuscular injections 
of acepromazine (0.04 mg/kg), oxymorphone (0.1 mg/kg), and atropine (0.04 mg/kg). Anesthesia 
was induced with intravenous (IV) administration of thiopental (10-15 mg/kg) and maintained 
with a mixture of halothane and oxygen.  Lactated Ringer's solution (10 ml/kg/hr IV) was 
administered during the anesthetic period.  Each dog was placed in left lateral recumbency.  The 
left rear leg and the right thoracic wall were prepared for aseptic surgery.  An autogenous 
cancellous bone graft was harvested from the proximal left tibia in a standard fashion (Johnson 
1988).  The graft was wrapped in a blood-soaked sponge for use later in the procedure and the 
incision site closed routinely. A dorsoventral incision was made through the skin and the 
cutaneous trunci muscle over the 5th intercostal space.  One of the four implants described in 
section 7.1.2. (BIA + collagen, collagen alone, gel capsule alone, or autogenous cancellous graft) 
was placed in each stab incision (Figure 16).   
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A simple interrupted suture of 4-0 wire was placed in the latissimus dorsi as a marker, 1.0 cm 
dorsal to each site of implantation.  The subcutaneous tissue and skin were closed in a routine 
fashion.   
 
b. Orthotopic evaluation of a bone-inducing agent in diaphyseal defects (Study II) 
Two female and two male adult Beagles were included in this experiment.  Radiographic and 
nuclear scintigraphic evaluations of both femurs were within normal limits.  Each dog was 
anesthetized, as previously described, and placed in right oblique recumbency.  The left leg was 
prepared for aseptic surgery, and an autogenous cancellous bone graft was harvested from the 
proximal left tibia (Johnson 1988). 
A standard lateral approach to the left femur was performed.  The periosteum was elevated and 
four 5.0 mm diameter defects were created in the lateral diaphyseal cortex of the femur with an 
orthopedic drill and a 5.0 mm drill bit (Figure 17).  Tape was placed around the drill bit 5 mm 
from the tip to act as a drill-stop and ensure a constant depth for all of the defects.   
 
 
 
 
Figure 16: Osteoinductive bioassay in 
five dogs. 
Four stab incisions were made in the 
right latissimus dorsi muscle over the 
4th, 5th, 6th, and 7th intercostal spaces. 
Figure 17: Orthotopic evaluation in diaphyseal 
unicortical defects. 
A sterile plastic template was used during drilling 
to ensure uniform spacing of the defects, 5,0 cm 
apart, along the diaphysis of the femur.  Each of 
the four treatments was assigned to one of the four 
drill holes, according to a Latin square design, to 
evaluate each filling material in all positions along 
the femoral diaphysis.   
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A wire suture was placed through the periosteum to mark the proximal end of the template.  The 
distance between the wire and the cortical defects was used to locate the healed defects for 
histological examination.  In each femur, one of the cortical defects was filled with autogenous 
cancellous graft, one with pure bovine collagen, and one filled with 10 mg of BIA mixed with an 
equal amount of bovine collagen.  All of the implants were packed in #4 gelatin capsules to 
provide retention at the surgical site.  The fourth defect was filled with an empty #4 gelatin 
capsule.  The surgical incision was closed in a routine fashion, and craniocaudal and lateral 
radiographic views of the left femur were immediately obtained.    
 
c. Use of a metaphyseal defect for evaluation of morselized grafts (Studies III-V): 
All mixtures (except autogenous cancellous grafts) were maintained at –700C in double 
polyethylene containers until surgery. A specialized miniature impactor (Figure 18) was designed 
to impact pellets at the same compactive effort as previously reported (equating to the energy 
used in a standard human impaction grafting, as determined by force plate analysis of impaction 
grafting on human femora, Brewster et al. 1999). 
 
Figure 18: Miniature impactor - grafting material is placed in a 15-mm-diameter 
impaction chamber (black arrow). A perforated piston (small white arrow) allows 
elimination of air and fluid during impaction. The impactor and piston are enclosed within 
a chamber (left grey block arrow) to improve stability. A brass cylinder (right white arrow) 
is dropped over the piston, to produce a compaction level similar to that generated during 
revision hip arthroplasty 
 
 
The dimensions of the impactor were adjusted from the original design to produce 15-mm-
diameter pellets.  The allocation of pellet to defect site was randomized according to a Latin 
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square design throughout the study, so that each treatment was evaluated more than once in all 
positions. 
 
Animals: 
Twenty-two adult female Grey-face sheep were included in Study IV, to evaluate a silicate-free 
bioactive glass. This breed of sheep was selected for tits large size, allowing creation of larger 
bone defects.  Body weight varied from 61 to 84 kg, with a mean and standard error of the mean 
(SEM) of 73 ± 1.04 kg.  Evaluation of tricalcium phosphate-hydroxyapatite aggregates in Study 
V, included eight adult female Grey-face sheep, with body weights ranging from 81 to 91 kg 
(mean: 84.94 ± 1.17 kg).  Data from all animals involved in Studies IV and V were analyzed to 
evaluate data specifically related to the metaphyseal defect model (Study III).  Animals were 
housed individually from two weeks prior to surgery until the end of the study. Home office 
regulations for the care and use of laboratory animals were followed throughout the study. 
 
Surgery: 
Prior to surgery, animals received intramuscular injections of morphine sulfate (0.1 mg/kg) and 
penicillin G procaine (10000 IU/kg).  Anesthesia was induced with intravenous administration of 
thiopental (10-14.5 mg/kg) and maintained with a mixture of halothane and oxygen.  Both rear 
legs were clipped and prepared for aseptic surgery.  In phase I of the study, a total of six 
unicortical defects were created in each sheep.  Defects were located in the subtrochanteric region 
of the femur, lateral aspect of the distal femoral metaphysic, and proximal medial tibia in both 
hind limbs.   
The approach to the greater trochanter and subtrochanteric area (Piermattei 1993) was modified 
to avoid tenotomy of the superficial gluteal muscle and elevation of the insertion of the vastus 
lateralis.  Instead, the subtrochanteric region was exposed by blunt dissection between the fibers 
of the vastus lateralis muscle (Figure 19a).  Exposure was maintained with Gelpi retractors.  A 
teflon plate was designed to guide the insertion of pellets into the defects and to standardize the 
location of the defects. The plate included two 2.7-mm-diameter holes, 1 cm proximal and distal 
to a central hole (15 mm in diameter).  The proximal femoral defect was created with one edge of 
the plate aligned with the proximal aspect of the greater trochanter.   
A standard approach to the distal femur (Piermattei 1993) was used to expose the lateral aspect of 
the distal femoral metaphysis.  The caudal distal femoral artery was preserved, and the defect 
created at the level of attachment of the gastrocnemius muscle (Figure 19b).   
A 4-cm-long skin incision was made directly over the medial proximal aspect of the tibia.  The 
knee joint was identified by arthrocentesis.  A unicortical defect was created at the cranial aspect 
of the origin of the popliteus muscle, with the edge of the teflon plate positioned just distal to the 
joint (Figure 19c). 
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At each site, a 5-mm-diameter pilot hole was drilled at low speed in the near cortex.  A drill-stop 
was placed 15 mm from the tip of the drill to ensure constant depth of defects.  A 15-mm drill 
was used to enlarge the unicortical defect. Cancellous bone retrieved during creation of the 
defects was kept in blood-soaked sponges until compaction.  Two 2.7-mm cortical screws were 
inserted into the corresponding holes of the teflon plate to maintain its alignment with the defect 
during insertion of pellets. The impaction chamber containing the pellet was aligned with the 
teflon plate over the corresponding bone defect.  A mallet was used to advance the piston within 
the compaction chamber by 15 mm, pushing the pellet into the defect.  All defects were therefore 
filled with pellets measuring 15 mm in diameter and length (Figure 20).  The plate and screws 
were removed and polymethylmethacrylate (Surgical Simplex®P, Howmedica Int. Inc., Ireland) 
was poured over the defect and into empty screw holes. 
 
 
 
Figure 19: Surgical approaches: 
 The proximal femoral defect (Figure a) is created after dissection between the fibers of the vastus lateralis
muscle (1).  The distal femoral defect (Figure b) is located at the level of attachment of the gastrocnemius
muscle (2), distal to the caudal distal femoral artery (3).  The third defect is drilled in the medial proximal
tibia (Figure c), with the edge of the teflon plate positioned just distal to the joint (4). 
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Figure 20: Insertion of pellets within metaphyseal defects.   
All defects are filled with pellets measuring 15 mm in diameter and length. 
 
 
In Study V, eight Grey-face sheep underwent surgical implantation of four defects located in the 
right and left distal femurs and proximal tibias.  The only difference compared with the surgical 
technique used in Phase I involved the use of two 1.6-mm-diameter Kirshner wires instead of 
screws to maintain the teflon plate during insertion of pellets (Figure 19c).  After removal of the 
plate, the wires were cut short, bent, and embedded in polymethylmethacrylate to seal each 
defect. 
 
 
7.3.2.  Postoperative evaluations 
 
a. Osteoinductive bioassays of BIA in dogs (Study II) 
The animals were evaluated daily for signs of infection.  Thoracic radiographs were obtained 
immediately after the operation and every two weeks until euthanasia six weeks after 
implantation.  The right latissimus dorsi muscle of each dog was then harvested and grossly 
examined.  High-resolution radiographs (Faxitron Series Model #43805-N, Hewlett Packard 
Corp., McMinnville, OR, USA), using nonscreen film (Kodak X-OMAT TL Film, Eastman 
Kodak Co., Rochester, NY, USA), were obtained and three sections were cut over each 
implantation site.  Each section was processed and evaluated histologically. 
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b. Osteoproductive properties of BIA after orthotopic implantation (Study II): 
The dogs were observed daily after the operation for signs of lameness or infection.  Nuclear 
scintigraphy and radiography (lateral and craniocaudal views) of both rear legs were performed at 
two-week intervals, starting 10 days after the operation. Craniocaudal and lateral nuclear scans 
were obtained 5 minutes (soft tissue phase), 2 hours (bone phase), and 24 hours (delayed bone 
phase) after intravenous injection of 1 mCi/Kg of 99 m Technetium-methylene diphosphonate. A 
50-pixel region of interest was centered over each of the 4 areas of increased activity in the left 
femur and corresponding areas of the right femur. A total radioactive uptake of each defect in the 
left femur was expressed as a percentage of uptake of the corresponding area of the right femur. 
The change in nucleotide uptake within each defect 10, 24, 38, and 52 days after surgery was 
calculated for the soft tissue, bone, and delayed (24 hours) bone phases at each evaluation time 
(Figure 21).  The change in nucleotide uptake 10, 24, 38, and 52 days after surgery is calculated 
for each of the soft tissue, bone, and delayed bone phases, as follows: 
Ratio (Left/Right) after surgery – Ratio (Left/Right) before surgery 
Ratio (Left/Right) before surgery 
 
 
 
 
 
Figure 21: Nuclear scintigraphy, soft tissue phase of dog 283 at day 10. 
Areas of increased uptake correspond to the surgical defects (arrows) created in the 
left femur. The uptake over corresponding areas of the right femur is measured as a 
control. 
 
 
All dogs were euthanized by administration of barbiturate overdose eight weeks after the 
operation.  Both femora were harvested, dissected free of soft tissues, except for the periosteum, 
and examined grossly.  Each specimen was fixed in 10% phosphate-buffered formalin.  High-
resolution radiographs (Faxitron Series Model #43805-N, Hewlett Packard Corp., McMinnville, 
OR, USA), using nonscreen film (Kodak X-OMAT TL Film, Eastman Kodak Co., Rochester, 
NY, USA), were obtained for all specimens.  With a slow-speed saw (Isomet Plus, Buehler Ltd., 
?
 ??
Left rear leg Right rear leg
Bladder---- 
??
---- Greater trochanter 
---- Proximal tibia 
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Lake Bluff, IL, USA), five-mm thick transverse slices were made over the four grafted sites of 
left femora (Figure 22).   
 
 
 
 
Dual energy X-ray absorptiometry (DEXA) was performed on each slice with a high resolution, 
single beam, small animal scan (QDR-2000, Hologic, Inc., Waltham, MA, USA).  Individualized 
regions of interest (R1 on figure 23) were constructed over the surgical site of each slice of the 
left femur.  Corresponding regions were constructed on each slice of the right femur using the 
"compare" feature of the software (Figure 23).  
 
 
 
 
The ratio: 
         BMD (or BMC) of a given region of the left femur 
-------------------------------------------------------------------------------- 
BMD (or BMC) of the corresponding area of the right femur 
 
was calculated for each region of interest (R1 on Figure 23). 
 
Two 5 µm-thick sections were cut in the center of each slice on the left femur and stained with 
hematoxylin and eosin for routine histology.  The healing of each defect was evaluated in a blind 
fashion and graded (Figure 24).   
Figure 22:  A slow-speed saw 
was used to cut 5-mm-thick 
transverse slices over the four 
grafted sites of  left femora. 
Slices were also obtained from 
the corresponding areas of  right 
femora.   
Figure 23:  Dual energy X-ray 
analysis 
 The bone scans were analyzed 
for bone mineral content (BMC) 
and density (BMD).    
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Histomorphometric analysis (BIOQUANT-OS/2, R&M Biometrics, Inc., Nashville, TN, USA) of 
the sections was also performed (Figure 25). 
 
 
 
Figure 24: Histological grading system, from left to right: 
• Grade 3: defect healed and entirely filled with bone 
• Grade 2: defect filled with bone and a small amount of connective tissue in the center of the
defect 
• Grade 1: defect filled with connective tissue and a small amount of woven bone along the
edges 
Figure 25:  
Histomorphometry 
 The areas of the defect filled 
with connective tissue 
(outlined in red) or bone were 
measured and expressed as a 
percentage of the total defect 
area (measured for each 
defect).  
 
 
?
?
?
?
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?
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c. Evaluation of idealized aggregates in ovine metaphyseal defects (Studies III, IV, V): 
In both Study IV (evaluation of a bioactive glass) and Study V (evaluation of tricalcium 
phosphate-hydroxyapatite composites), postoperative radiographs were obtained prior to 
recovery. Animals recovered in a support sling for 12 hours and were then allowed to mobilise 
over 7 weeks (Phase I, n=11) and 14 weeks (Phase I, n=11; Phase II, n= 8) in individual pens.  
Analgesia was provided via intramuscular administration of morphine (0.1 mg/kg) 4 hours after 
surgery and flunixin meglumine (1 mg/kg once daily) for 3 days after surgery.  Double pulse 
oxytetracycline (30 mg/kg at days 23 and 35) and alizarin complexone (30 mg/kg, day 84) were 
administered at 4 and 12 weeks, respectively. After sheep were euthanized, the distal aorta was 
perfused with 10% buffered formaldehyde.   
 
Computed tomography: 
After removal of the skin, the limbs were fixed in 10% buffered formaldehyde and evaluated with 
helical computed tomography (CT) (Hi speed advantage, GE medical systems, Milwaukee, WI, 
USA).  Transverse scans of the limbs were made, using 3-mm-thick contiguous slices at 100 kV 
and 80 mA.  The CT scans were evaluated for any orthopedic pathology and the position of the 
polymethylmethacrylate seal in relation to the corresponding defect was noted.  The average 
pixel value of a 5-mm2 area (indicated as a square) centered over each defect was divided by that 
of the intact adjacent cortex (indicated as X) and expressed as a percentage (Figure 26). 
 
x
 
Figure 26: Computed tomography 
Average  pixel value of the center of the defect (5 mm2 square) 
Ratio (%):   ---------------------------------------------------------------------------X 100 
Pixel value of intact adjacent cortex(X) 
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Histology  
All soft tissue was removed from the bones.  High-resolution radiographs were obtained prior to 
cutting 2-cm-wide sections centered over each defect.  The sections were divided into two 1-cm-
wide blocks. For each defect, one block was decalcified in ethylenediaminetetraacetic acid 
(EDTA) and embedded in paraffin (Figure 27).  At least two 5-µm-thick sections were cut from 
each block and stained with hematoxylin and eosin.  Cortical healing of each defect was 
evaluated with the same grading system used in the evaluation of a bone-inducing agent 
(described above).  Two independent investigators unaware of the material filling each defect 
reviewed all sections. 
 
 
 
 
Histomorphometry and fluorescence: 
The other 1-cm-wide block of bone from each defect was stored in alcohol, defatted in xylene 
and embedded in methylmethacrylate (Figure 27).  At least three 50-µm-thick sections were cut 
with a diamond saw (Isomet 2000, Buehler Kraut Kramer, Coventry, UK).  In both phases, the 
mineral apposition rate (MAR) of an area of intact cortex adjacent to the defect was measured.  In 
Study IV, mineral apposition rates were determined at the superficial aspect of the periphery of 
each defect.  In Phase V, mineral apposition rates were measured in four areas within each defect: 
superficial center, superficial periphery, deep center, and deep periphery.  All measurements 
within the defect were averaged for comparison between treatment groups, side, and location of 
defect. 
At least two sections per block were stained with Paragon and used for histomorphometry.  Each 
entire cross section was captured using a digital camera (3CDD, JVC).  Defined areas were 
measured with image analysis QS 300 (Imaging Associates 1999, version 3.0). The areas within 
the cortical defect filled with newly formed bone, implants, and fibrous tissue were expressed as 
percentages of the total area of the cortical defect.  The percentage of the defect filled with bone 
(remnants of allograft and new bone) was also determined. 
 
Figure 27: Preparation of sections. 
One half of the 2- cm-wide block 
centered over each defect is 
decalcified and processed for routine 
histology (left).  The other half is 
prepared for undecalcified sections 
(right), histomorphometry and 
measurement of mineral apposition 
rates. 
 46 
 
7.4. STATISTICAL ANALYSES 
 
7.4.1. Biomechanical properties of frozen corticocancellous bone: 
 
Student's paired t-tests were used to identify statistical differences within pairs of bones for each 
parameter.  Six physical properties were evaluated for each testing.  Maximal torque (ultimate 
strength), angular deformation at failure (ultimate strain), torque and angular deformation at yield 
point, energy absorbed to failure (toughness), and torsional stiffness were analyzed for statistical 
significance.  Maximal bending moment, displacement at failure, bending moment and 
displacement at yield point, energy absorbed to failure, and bending stiffness were evaluated for 
bending tests.  Data obtained on ribs were analyzed separately from those obtained on metatarsal 
and metacarpal bones.  All differences were considered significant at a probability level of 95% 
(p<0.05). 
 
7.4.2.  Evaluation of a bone-inducing agent: 
 
Densitometric and histomorphometric data were analyzed for statistical significance with one-
way analysis of variance (ANOVA). Significant differences between treatments were determined 
with a pairwise comparison of treatment least squares means.   Significance level was set at p < 
0.05. 
 
7.4.3.  Evaluation of the metaphyseal defect model and osteoconductive aggregates:   
 
Body weights were compared between groups with a Student’s t-test. This test was also used to 
compare computed tomographic and histomorphometric data between sides of implantation (left 
and right) and defect location in Phase II.  Computed tomographic and histomorphometric data 
were compared between treatment groups as well as defect location in Phase I (3 sites) using 
repeated measures analysis of variance (ANOVA).  When a significant difference was found, 
Tukey’s “honestly significant difference” (HSD) method was used.  Our priority was to compare 
treatments with the clinical control (allograft) in Phase I; Dunnett’s method was used to allow for 
multiple comparisons.  In Phase II, all pairwise comparisons were made for treatment means 
using Tukey’s HSD method. 
Nonparametric data were analyzed with the Wilcoxon signed-rank test and Friedman’s method.  
Histological grades consisted of three ordered categories in Phase I. In Phase II, interinvestigator 
consistency, as well as the implicit assumption of an interval scale, was verified. Mean values 
were taken from the two observers, resulting in 5 ordered categories. The significance level was 
set at p=0.05 in all tests. All results are given as mean values ± standard error of the mean. 
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8.  RESULTS 
 
 
8.1.  BIOMECHANICAL TESTS (Study I): 
 
No abnormality was detected on examination of high-resolution radiographic views obtained for 
each bone. Load deformation curves in bending and torsion all had a similar appearance, as 
illustrated in Figure 28.  
 
 
Figure 28: Load deformation curves.  
To the left: torsion test of a second left metacarpal bone. Right: bending test of a 
third right metacarpal bone. 
 
 
However, differences were found between storage techniques when bones were tested in bending 
to failure.  Results of bending and torsion tests are presented in Tables 6 and 7.  
 
 
Table 6: Biomechanical properties of ribs and metacarpal (MTC) and metatarsal (MTT) bones, frozen 
with or without (w/o) normal saline solution (NSS), tested in 4-point bending to failure. 
 
Treatment No. of 
bones 
Slope (Nm/m) Displacement 
at yield point 
(mm) 
Bending 
moment at 
yield point 
(Nm) 
Displacement 
at failure 
(mm) 
Bending 
moment at 
failure (Nm) 
Energy 
absorbed at 
failure 
(mm Nm2) 
Ribs with NSS 7 815.9± 79.6 1.70± 0.10 1.3± 0.01 5.34± 0.62* 2.08± 0.06 6.98± 0.88* 
Ribs w/o NSS 7 904.3± 98.0 1.80± 0.24 1.36± 0.18 4.38± 0.36* 2.09± 0.13 5.44± 0.69* 
MTC, MTT with NSS 10 2969.1± 359.7 1.67± 0.12 3.98± 0.39 3.91± 0.36* 5.64± 0.48 13.45± 1.68* 
MTC, MTT w/o NSS 10 3259.4± 233.3 1.75± 0.22 4.32± 0.23 3.01± 0.38* 5.78± 0.22 9.31± 1.41* 
 Data are expressed as mean ± SEM where applicable.  
* p<0.05 
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Table 7: Biomechanical properties of metacarpal (MTC) and metatarsal (MTT) bones, frozen with or 
without (w/o) normal saline solution (NSS), tested to failure in torsion. 
 
Treatment No. of 
bones 
Slope (Nm/deg) Angular 
deformation at 
yield point 
(deg) 
Torque at 
yield point 
(Nm) 
Angular 
deformation at 
failure (deg) 
Torque at 
failure (Nm) 
Energy 
absorbed at 
failure 
(Nm deg) 
MTC, MTT with NSS 11 0.17± 0.01 13.70± 0.84 1.99± 0.21 17.43± 0.77 2.34± 0.23 20.62± 2.5 
MTC, MTT  w/o NSS 11 0.18± 0.01 13.63± 0.49 2.03± 0.14 19.48± 1.47 2.53± 0.18 25.62± 3.0 
Data are expressed as mean ± SEM where applicable. Deg=degrees 
 
 
No significant difference was found in torsion.  The displacement and energy absorbed at failure 
in bending were significantly greater when metacarpal and metatarsal bones were frozen in 
isotonic saline solution (Figure 29).  
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Figure 29: Load deformation curves of metacarpal and metatarsal bones 
tested to failure in bending after 1 year of storage at –20oC with or without 
(Dry) normal saline solution (NSS).  
Graphs are average plots and the points are the averages for each group.  
Displacement and energy absorbed at failure were significantly greater when 
bones were stored with NSS. 
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Similar results were found for ribs (Figure 30):   
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Figure 30: Load deformation curves of ribs tested to failure in bending 
after 1 year of storage at –20oC with or without (Dry) normal saline 
solution (NSS). See Figure 29 for further information.. 
 
 
8.2.  OSTEOPRODUCTIVE PROPERTIES OF A BONE-INDUCING AGENT (Study II) 
 
8.1.1. Ectopic bone formation  
 
An ossicle of bone formed by two weeks after intramuscular implantation of BIA in all mice 
(Figure 31).  
 
 
 
 
Figure 31: Osteoinductive 
bioassays in mice .   
An ossicle of bone formed 
within 2 weeks after 
intramuscular implantation of 
BIA (hematoxylin and eosin, 
X2).  
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Complications were not encountered during or after the operation in dogs. However, no evidence 
of cartilage or bone formation was found radiographically, grossly or histologically in any of the 
intramuscular implantation sites in dogs (Figure 32).  A variable degree of fibrosis and condensed 
muscle cells with large nucleoli, consistent with skeletal muscle regeneration, was found at all 
implantation sites.  Mild to moderate chronic inflammation was seen in half of the surgical sites.  
Two of the five sites implanted with BIA had increased amounts of chronic inflammation.   
 
 
 
Figure 32: Microphotograph of the latissimus dorsi muscle six weeks after 
implantation of a bone-inducing agent (hematoxylin and eosin, X2). Fibrosis and 
mild inflammation was found, but there was no evidence of cartilage or bone. 
 
 
8.2.2.  Orthotopic bone formation 
The dogs were intermittently weight-bearing lame (grade1) the day after the creation of four 
cortical defects in the left femora.  The lameness resolved within 10 days of surgery. 
 
a. Radiographs 
All of the defects were visible on postoperative radiographs and became more radio-opaque over 
the course of the study (Figure 33).  Defects filled with autogenous cancellous grafts were more 
radio-opaque than other defects immediately after the operation and remained so throughout the 
study.  They were barely visible on radiographs taken 52 days after surgery.  Defects filled with 
BIA implants appeared to be the least radio-opaque of all defects and were easily visualized on 
radiographs obtained at the end of the study.  The radio-opacity of the defects filled with bovine 
collagen or a gelatin capsule was intermediate.  Evidence of microfractures was not se en on high- 
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resolution radiographs obtained eight weeks after the operation, and all of the defects were 
readily identified (Figure 33). 
 
 
Figure 33: Postoperative radiograph of a canine femur with four 
cortical defects (Left) and high-resolution radiographs (Right) eight 
weeks after implantation of: a) gelatin capsule, b) bovine collagen, c) 
autogenous cancellous bone, d) 10 mg of BIA mixed with an equal 
amount of collagen. 
 
b. Gross examination 
Soft tissue reaction was not observed on gross examination of the femora.  The defects filled with 
BIA were grossly more apparent than other defects (Figure 34).  They seemed to be filled with a 
vascular tissue and appeared as dark depressions in the femoral cortex.  Defects treated with the 
other implants varied in appearance.  Some looked grossly similar to defects filled with BIA, 
while other appeared as slight depressions in the femoral cortex. 
 
 
 
Figure 34: Gross appearance the canine femur radiographed above with four cortical 
defects, eight weeks after implantation of: a) gelatin capsule, b) bovine collagen, c) 
autogenous cancellous bone, d) 10 mg of BIA mixed with an equal amount of collagen. 
a 
a 
b 
c 
d 
b 
c 
d 
a b c d 
 52 
c. Nuclear scintigraphy 
The results of the nuclear scintigraphic soft tissue phase, bone phase, and delayed bone phase are 
summarized in Figures 35, 36, and 37, respectively.  
The radionucleotide uptake increased in all three phases 10 days after surgery and returned to 
preoperative values in the subsequent evaluations.  In the soft tissue phase (Figure 35), uptake 
was significantly increased 10 days after surgery in defects treated with autogenous cancellous 
graft as compared with defects treated with BIA or a gelatin capsule.  
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There was no difference between groups in the subsequent evaluations.  In the bone phase 
(Figure 36), no significant difference was found in the uptake between treatment groups or 
between any of the evaluation times. 
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Figure 35: Nuclear scintigraphy – Soft tissue phase measured 5 minutes after 
intravenous injection of 99 m Technetium-methylene diphosphonate. 
A,B: groups with different letters differ statistically (p<0.05) 
Figure 36: Nuclear scintigraphy – Bone phase measured 2 hours after 
intravenous injection of 99 m Technetium-methylene diphosphonate. 
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In the delayed bone phase (Figure 37), uptake was significantly increased in defects treated with 
BIA and autogenous graft as compared with defects treated with collagen or gel capsule at day 
10.  No significant difference was present between treatment groups at other evaluation times.  
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d. Densitometry 
The bone mineral density of the regions containing the defects filled with cancellous graft, BIA, 
collagen, or a gelatin capsule was 97.0 ± 8.0 (SEM)%, 90.8 ± 10.6%, 87.6 ± 8.3% and 86.0 ± 
5.5% that of a corresponding area of the intact femur, respectively.  The bone mineral content of 
the regions containing the defects filled with cancellous bone, BIA, collagen or a gelatin capsule 
was 93.5 ± 10.6%, 88.8 ± 24.4%, 86.1 ± 16.5%, and 72.0 ± 10.1% that of a corresponding area of 
the intact femur, respectively.  A statistical difference was not found between treatment groups.  
 
e. Histology and histomorphometry 
Healing of the cortical defects was evaluated by histology and histomorphometry (Table 8).  BIA, 
collagen, or gelatin residue was not found.  The defects treated with autogenous cancellous graft 
were mostly or entirely filled with trabecular bone.  Three of four defects treated with a gel cap 
alone were healed; however, none of the BIA-filled defects was completely filled with bone eight 
weeks after the operation.   Numerous lymphocytes were found in one of four defects treated with 
BIA.   
Histomorphometry correlated well with the histological grades; defects filled with autogenous 
cancellous bone contained the greatest amount of bone and least amount of connective tissue of 
any of the treatment groups.  The defects filled with BIA contained the least amount of bone and 
the greatest amount of connective tissue (Figure 38).  Due to the small number of samples, 
differences were not statistically significant. 
Figure 37: Nuclear scintigraphy – Delayed bone phase measured 24 hours after 
intravenous injection of 99 m Technetium-methylene diphosphonate. 
A,B: groups with different letters differ statistically (p<0.05) 
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Table 8:  Histological grades and histomorphometry of cortical defectsin four dogs eight weeks after 
treatment with cancellous bone, 10 mg of a bone-inducing agent (BIA) extracted from a human Saos-2 cell 
line mixed with 10 mg bovine collagen, 20 mg bovine collage,  or a gelatin capsule. 
 
 
Treatment 
 
Grade I 
(Nb of defects) 
 
Grade II 
(Nb of defects) 
 
Grade III 
(Nb of defects) 
 
% of defect  
area filled with 
bone 
 
% of defect  
area filled with 
fibrous tissue 
 
Cancellous bone 
(n=4) 
 
0 
 
1 
 
3 
 
94.2 ± 4.5 
 
5.8 ± 4.5 
 
BIA + Collagen 
(n=4) 
 
 
2 
 
 
2 
 
 
 
0 
 
 
77.2 ± 3.0 
 
 
22.8 ± 3.0 
 
Collagen 
(n=4) 
 
 
0 
 
 
3 
 
 
1 
 
 
 
87.2 ± 8.6 
 
 
12.8 ± 8.6 
 
Gelatin capsule 
(n=4) 
 
 
1 
 
 
0 
 
 
3 
 
 
 
89.6 ± 9.1 
 
 
10.4  ± 9.1 
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77%
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Fibrous Tissue
Collagen
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13%
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90%
10%
 
Figure 38: Histomorphometry results. Areas of the defects filled with bone and 
fibrous tissue are expressed as % of the total defect area for each treatment group. 
The defects filled with BIA contained the least amount of bone and the greatest 
amount of connective tissue. 
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8.3. EVALUATION OF AN OVINE METAPHYSEAL DEFECT MODEL (Study III) 
 
Data obtained on sheep in Studies IV and V was combined to evaluate the ovine metaphyseal 
defect model. 
 
8.3.1. Complications 
 
Sheep in Study V were heavier than those in Study IV, with a mean body weight of 84.94 ± 1.17 
kg (SEM) as compared with 73 ± 1.04 kg.  In Study IV, one sheep died of anesthetic 
complications during recovery. In addition, four of 21 sheep fractured one femur within a week 
of surgery (19%).  The fractures were spiral, originating from the distal femoral defect in three 
sheep. Two of these sheep had been operated on at the beginning of the study, and the distal 
defect of both fractured femora was found to be too close to the diaphysis, proximal to the caudal 
distal femoral artery. Landmarks were subsequently adjusted and defects created distal to the 
caudal distal femoral artery, at the level of attachment of the gastrocnemius muscle.  In the fourth 
sheep, the fracture originated from the proximal femoral defect.  No postoperative complication 
occurred in study V.   
Migration of the cement seal was noted in 25 out of 102 defects (24.2%) in study IV: 18 defects 
(17.6%) were completely exposed and 7 defects (6.9%) were partially exposed. 
Polymethylmethacrylate penetrated within 5 of the 17 empty defects (29.4%, Figure 39).  These 
five defects were excluded from the study.  All defects in the proximal femur were found to reach 
the intertrochanteric fossa on postmortem examination.  None of these complications occurred in 
Study V.   
 
 
 
 
8.3.2.  Effect of implantation site  
 
Computed tomography results evaluating the effects of side and site of implantation are 
summarized in table 9.  No difference was found between sites of implantation in study IV, 
whereas in study V, distal femoral defects were denser than defects located in the proximal tibia.   
 
Figure 39:  Bone cement seal engaging an empty 
defect in the proximal tibia.  
Polymethylmethacrylate has been elevated (block 
arrow) from the bone to visualize the unhealed 
defect (arrow).  This defect was excluded from the 
study. 
→
⇒
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Table 9: Computed tomography.   
The mean pixel value measured in a 5-mm2 area centered over the defect is expressed as a 
percentage of the pixel value of intact adjacent cortical bone (% ± standard error). Effect of side 
(all sites amalgamated) and site (right and left included) of implantation. 
 
 Study IV 
7 weeks 
Study IV 
14 weeks 
Study V 
14 weeks 
Proximal femur 23.13 ± 5.09 23.65 ± 2.98 N/A 
Distal Femur 19.71 ± 5.29 27.8 ± 3.05 67.48 ± 3.57* 
Tibia 21.05 ± 5.42 18.58 ± 3.05 52.15 ± 3.57* 
Left limb 21.66 ± 4.01 24.93 ± 2.47 61.24 ± 3.57 
Right limb 21.13 ± 4.61 21.76 ± 2.47 58.39 ± 3.57 
* p<0.05: density was higher in distal femoral defects than tibial defects in Study V 
 
 
Side and location of the defect seemed to influence the healing of the defects created in Study V; 
distal femoral defects scored higher than tibial defects (Table 10). Although not statistically 
significant, a similar trend was found in Study IV.   
 
 
Table 10: Histological grades of cortical defects filled with morselized impacted grafting 
materials. 
 Grades increase from 1 to 3 with improved healing (± standard error). Effects of side (all sites 
amalgamated) and site (right and left included) of implantation. 
 
 Study IV 
7 weeks 
Study IV 
14 weeks 
Study V 
14 weeks 
Proximal femur 2.17 ± 0.23 2.09 ± 0.17 N/A 
Distal femur 1.92 ± 0.24 2.27 ± 0.18  2.44 ± 0.15* 
Tibia 1.5 ± 0.23 1.86 ± 0.17 1.81 ± 0.15* 
Left limb 1.94 ± .018 2.21 ± 0.14 2.03 ± 0.15 
Right limb 1.78 ± 0.2 1.94 ± 0.14 2.22 ± 0.15 
* p<0.05: distal femoral defects scored higher than tibial defects in Study V 
 
 
Histomorphometry correlated well with histological grades. In Study IV, tibial defects contained 
less bone and more fibrous tissue than proximal femoral defects 7 weeks after surgery but not at 
week 14 (Table 11).  New bone predominated over dead allograft within defects, representing 89 
± 2.89% and 94.22 ± 6.08% of all bone within the defect area at 7 and 14 weeks respectively.  
Tibial defects contained less new bone than proximal and distal femoral defects at 7 weeks, but 
no difference was found at 14 weeks.   
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Table 11: Histomorphometric analysis in Study IV. 
 Area of cortical defects filled with bone (newly formed bone and allograft), new bone, 
and fibrous tissue at, 7 and 14 weeks after surgery (% ± standard error). Effects of side 
(all sites amalgamated) and site (left and right included) of implantation. 
 
 
 
 % bone % new bone % fibrous tissue 
7 weeks 36.28 ± 3.84* 31.65 ± 3.12A 64.17 ± 3.78* Proximal 
Femur 
14 weeks 42.68 ± 6.89 40.63 ± 6.55 58.99 ± 6.33 
7 weeks 30.91 ± 4.15 29.54 ± 3.37 A 69.25 ± 4.09 Distal  
Femur 
14 weeks 47.22 ± 6.47 45.24 ± 6.15 44.76 ± 5.95 
7 weeks 18.47 ± 3.07* 15.98 ± 2.49 B 81.87 ± 3.02* Tibia 
 
14 weeks 53.83 ± 5.97 49.65 ± 5.67 43.12 ± 5.48 
7 weeks 32.25 ± 2.82 28.12 ± 2.29 67.68 ± 2.78 Left  
limb 
14 weeks 49.19 ± 5.13 45.47 ± 4.88 49.87 ± 4.72 
7 weeks 24.86 ± 3.07 23.33 ± 2.49 75.85 ± 3.02 Right  
limb 
14 weeks 46.63 ± 5.34 44.87 ± 5.07 48.04 ± 4.91 
*:p<0.05: Defects in the proximal femur contained more bone and less fibrous tissue 
than tibial defects at 7 weeks.  
A,B
: Different letters indicate differences between implantation sites. Defects in the 
proximal and distal femur contained more new bone than tibial defects at 7 weeks. 
 
 
In Study V, greater amounts of synthetic agents were found after 14 weeks in the distal femur 
compared to the proximal tibia (Table 12).  A tendency (p=0.2) was also present for distal 
femoral defects to contain more bone than tibial defec ts.  
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Table 12: Histomorphometry in Study V.   
Area of the defects filled with bone and with implants 14 weeks after implantation of tricalcium 
phosphate and hydroxyapatite aggregates (% of defect area ± standard error). 
 
 Phase II 
(14 weeks) 
% bone 
Phase II 
(14 weeks) 
% implants 
Distal femur 47.8 ± 2.7 43.02 ± 2.55* 
Tibia 42.8 ± 2.79 29.86 ± 2.55* 
Left limb 42.84 ± 2.79 36.93 ± 2.55 
Right limb 47.77 ± 2.7 35.95 ± 2.55 
* p<0.05: Greater amounts of more synthetic agents were found in the distal femur than tibia. 
 
 
The bone-labelling regimen selected in this study was adequate for visualization of bone 
fluorochromes and measurement of mineral apposition rates (Figure 40). 
 
 
 
 
Figure 40: Bone fluorescence in Study V. 
 The double pulse of oxytetracycline (block arrow) and alizarin complexone 
(arrow) are identified under polarized light to measure mineral apposition rates 
at 4 and 12 weeks after surgery, respectively. 
 
 
Mineral apposition rates did not differ between sites of implantation and treatments throughout 
the study.  The double pulse of oxytetracycline administered at 4 weeks after surgery allowed 
measurements of mineral apposition rates (MAR) equal to 1.88 ± 0.11 and 2.1 ± 0.07 µm/day in 
Study IV sheep euthanized at 7 and 14 weeks, respectively.  MARs measured in the defects were 
generally 40-50% higher than those measured in matched adjacent intact cortex during the same 
→ 
TCP-HA
⇒
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period (1.54 ± 0.19 and 1.57 ± 0.09 µm/day in sheep euthanized at 7 and 14 weeks, respectively). 
The mineral apposition rates measured in the defects at 12 weeks decreased to 1.13 ± 0.2 µm/day.  
Similar results were obtained in Study V, where MARs decreased from 2.57 ± 0.3 µm/day at 4 
weeks to 1.45 ± 0.18 µm/day at 12 weeks.  Within each defect of Study V, MARs at 4 weeks 
after surgery were higher in the center rather than the periphery of the defect, especially at the 
most superficial aspect of the cortical defect (Table 13).  No difference was found at 12 weeks, 
but there was a trend (p=0.06) for deeper positions to have lower MARs than superficial 
positions.  
 
Table 13: Mineral apposition rates (µm/day ± standard error of mean) measured at the 
superficial periphery, superficial center, deep periphery, and deep center within 31 metaphyseal 
defect at 4 and 12 weeks after surgery. 
 
 4 weeks 12 weeks 
Superficial periphery 2.29 ± 0.08* 1.63 ± 0.08 
Superficial center 2.87 ± 0.08* 1.39 ± 0.08 
Deep periphery 2.41 ± 0.08 1.40 ± 0.08 
Deep center 2.54 ± 0.08 1.38 ± 0.08 
* p<0.05: MAR were higher in the superficial center of defects than at the periphery. 
 
 
8.3.3. Value of the model in the evaluation of impacted aggregates 
 
The limitations related to the number of defects per limb and the migration of the cement seal are 
presented under complications. All defects were identified by computed tomography. The 
placement of Kirshner wires in Study V did not impede measurements of the pixel value within 
the defect.   
Empty defects used as negative controls in Study IV had the lowest density of all groups at 7 
weeks, but their density increased thereafter.  At 14 weeks, they did not differ from the positive 
(autogenous graft) and clinical (allograft) controls (Figure 41, Section 8.4.1.). In Study IV, the 
density of defects filled with compacted allograft or autogenous cancellous graft was similar at 7 
and 14 weeks after surgery.  No difference was found in any other parameter evaluated between 
autogenous bone and allograft in Study IV.  Allograft seems to act as a suitable positive control 
for evaluation of synthetic biomaterials with the model described here. It was therefore selected 
as a control group in Study V. 
Healing of the defects was also evaluated via histology and histomorphometry.  In both phases, a 
layer of fibrous tissue was found at the graft-cement junction.  In Study IV, particles of dead bone 
were identified in all defects filled with allograft, either alone or mixed with synthetic agents.  
Although the presence of autogenous cancellous graft within the defect was more difficult to 
verify, all defects in this treatment group healed well.  Remnants of the synthetic agent tested in 
Study IV could only be identified in one specimen at 7 weeks.  However, remnants of implants 
could be seen 14 weeks after surgery in all defects filled with the ceramics evaluated in Study V.  
Migration of pellets therefore seems unlikely. 
The results related to individual treatment groups are presented in sections 8.4.and 8.5.  The 
model was useful in evaluating the incorporation, biocompatibility, and in vivo dissolution rates 
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of the materials tested.  Differences were found between treatments groups in both phases, 
allowing comparison of the osteoconductive properties of the agents tested.  
 
 
8.4.  IN VIVO DISSOLUTION OF A SILICATE-FREE BIOACTIVE GLASS (Study IV) 
 
Aerobic and anaerobic cultures of all implants used in this study were negative.  Complications 
are reported in the section dealing with the evaluation of the model. 
 
8.4.1.  Computed tomography 
 
Computed tomography results are summarized in Figure 41.  
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Figure 41: Computed tomography. The mean pixel value measured in a 5-mm2 area centered
over the defect is expressed as a percentage of the pixel value of intact adjacent cortical bone (%
± standard error). 
• Empty: empty defect (negative control) 
• Autogenous: fresh autogenous corticocancellous bone (positive control) 
• Allograft: corticocancellous allograft (clinical control) 
• BG1: Allograft idealized with particles of Corglaes® 
• BG2: 50/50 mixture of idealized allograft/Corglaes® 
• BG3: Idealized Corglaes® 
Different letters indicate statistical difference between treatments (A,B at 7 weeks, CDE at 14 
weeks): Empty defects and treatment BG3 are different from the Allograft and Autograft groups at 
7 weeks. At 14 weeks, treatments BG2 and BG3, containing 50% and 100% bioactive glass, 
respectively, are different from the Allograft group.  
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The pixel value (mean ± SEM) of intact cortical bone was 1860 ± 46.0 and did not differ between 
implantation sites.  The pixel value (mean ± standard deviation) of pellets prior to implantation 
was 545.1 ± 210.7 for idealized allograft, 694.5 ± 214.7 for allograft idealized with Corglaes®, 
1245.6 ± 217.3 for the 50/50 mixture of allograft/Corglaes®, and 1734.5 ± 204.1 for idealized 
Corglaes®.  Other computed tomography results are presented in Figure 41.  Seven weeks after 
surgery, the density of empty defects and defects filled with idealised Corglaes® was lower than 
that of defects filled with allograft (p<0.05).  Fourteen weeks after implantation, defects filled 
with allograft had a higher pixel value ratio than defects filled with 50% or more Corglaes® 
(treatment groups 5 and 6). The pixel value of defects filled with allograft idealized with 
Corglaes®  was similar to that of defects filled with autograft or allograft. 
 
8.4.2.  Histology 
 
In all defects, a layer of fibrous tissue was found at the cement-graft junction, consistent with a 
reaction to polymethylmethacrylate.  Mild inflammation was found in only three defects in one 
sheep euthanized at 14 weeks: one of the defects was filled with allograft idealized with 
Corglaes®, the second with the 50/50 mixture, and the third with allograft.  Although particles of 
dead bone were identified in all defects filled with allograft, remnants of Corglaes ® were found in 
only one specimen at seven weeks after surgery (Figure 42).   
 
Figure 42: Paragon-stained undecalcified section (magnification X10) of the trabecular 
area: remnants of bioactive glass (black arrows) 7 weeks after implantation of an impacted 
idealized aggregate of Corglaes® in the right distal femoral metaphysis of a sheep. The 
perimeter of particles attached to new bone varied between 63.18%  and 87.69%. 
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No particle of Corglaes® was seen within cells, consistent with removal of controlled release 
glasses by dissolution rather than cellular degradation.  The healing of the defect was poor and a 
histological grade of 1 (out of 3) was assigned to this defect. The area of the cortical defect 
contained 7.8% bone (all new), 13% bioactive glass, and 78.6% connective tissue.   
Histological grades did not differ between treatment groups seven weeks after surgery (Figure 
43).  However, defects containing more than 50% Corglaes® obtained lower grades than the 
clinical control at 14 weeks (Figure 43).   
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8.4.3.  Histomorphometry 
 
Histomorphometric data confirmed histology results (Table 14).  Most (85.56 ± 7.2%) of the 
bone found within each defect containing allograft alone or mixed with synthetic graft consisted 
* *
Figure 43: Histological grades (mean) of metaphyseal defects filled with impacted
morselized grafts.  Grades increase from 1 to 3 with healing (mean ± standard error). 
• Empty: empty defect (negative control) 
• Autogenous: fresh autogenous corticocancellous bone (positive control) 
• Allograft: corticocancellous allograft (clinical control) 
• BG1: Allograft idealized with particles of Corglaes® 
• BG2: 5  50 mixture of idealized allograft / Corglaes® 
• BG3: Idealized Corglaes® 
*
 indicates a statistical difference between the treatment and allograft (clinical control):
Treatments BG2 and BG,3 containing 50% and 100% bioactive glass, respectively, are
different from the Allograft group. 
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of newly formed bone seven weeks after implantation.  The rest of the defect was filled with 
particles of dead bone and fibrous tissue.  By 14 weeks, 94.97 ± 4.3% of the bone found in these 
defects was new, with very little evidence of allograft remnants.  
 
 
 
 
 
 
 
 
 
 
   % bone % new bone % fibrous tissue 
7 weeks 11.83 ± 7.19 * 12.90 ± 5.84 * 90.33 ± 7.08 * Empty 
Defect 14 weeks 52.68 ± 10.88 50.36 ± 10.35 47.73 ± 10.93 
7 weeks 38.90 ± 4.55 35.03 ± 3.69 61.07 ± 4.48 Autogenous 
Graft 14 weeks 52.39 ± 8.88 46.30 ± 8.45 47.82 ± 8.93 
7 weeks 36.34 ± 5.09 31.62 ± 4.13 63.39 ± 5.01 Idealised 
Allograft 14 weeks 64.88 ± 8.88  58.75 ± 8.45 33.49 ± 8.93 
7 weeks 29.69 ± 4.55  25.31 ± 3.69 70.14 ± 4.48 BG1  
BG1 14 weeks 49.48 ± 8.88 48.63 ± 8.45 50.83 ± 8.93 
7 weeks 39.60 ± 4.55 35.51 ± 3.69 60.03 ± 4.48 BG2 
BG2 14 weeks 28.78 ± 8.43 # 28.33 ± 8.02 # 71.27 ± 8.47 # 
7 weeks 14.96 ± 5.87 * 13.97 ± 4.77 * 85.64 ± 5.78 * BG3 
BG3 14 weeks 38.78 ± 8.88 # 38.64 ± 8.45 60.82 ± 8.93 # 
For each parameter, * and #  indicate a statistical difference between the group and the 
allograft (clinical control) at 7 and 14 week,  respectively.  
 
Empty defects and those filled with Corglaes® alone contained less new bone and more fibrous 
tissue than defects filled with allograft seven weeks after surgery.  Empty defects gradually filled 
with bone and by 14 weeks contained as much bone as defects treated with allograft, autograft, or 
Table 14: Histomorphometric analysis - percentage of the defect area filled with bone,
new bone, and fibrous tissue (mean ± standard error). 
• Empty: empty defect (negative control) 
• Autogenous: fresh autogenous corticocancellous bone (positive control) 
• Allograft: corticocancellous allograft (clinical control) 
• BG1: Allograft idealized with particles of Corglaes® 
• BG2: 50/50 mixture of idealized allograft/Corglaes® 
• BG3: Idealized Corglaes® 
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allograft idealized with Corglaes® (p>0.05).  However, defects filled with Corglaes® alone or 
mixed with allograft in a 50/50 ratio contained less bone and more fibrous tissue than the clinical 
control.  
Mineral apposition rates (MAR) did not differ between treatment groups throughout the study.  
 
 
8.5. OSTEOCONDUCTIVE PROPERTIES OF IMPACTED TRICALCIUM 
PHOSPHATE – HYDROXYAPATITE 
 
Postoperative radiographs showed that the defects were correctly positioned. No perioperative 
complications were encountered. All sheep were bearing weight on the affected limbs within five 
days of surgery. Minor soft tissue inflammation was noted on gross examination of two defects 
where the polymethylmethacrylate plaque had loosened. 
 
8.5.1. Computed tomography 
 
The results of CT-derived densitometry are summarized in Figure 44. Defects implanted with 
mixtures containing TCP-HA had higher mean values than defects treated with allograft 
(p<0.05). Mean values for defects treated with “TCP80” (BoneSave™), “HA80”, and “HA80-3 
sizes” were not significantly different from each other (p>0.05). 
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Figure 44: Computed tomography – values are expressed as a percentage of defect 
density over adjacent cortical density (means ± SEM). 
• Bone: impacted idealized morselized allograft 
• TCP80: idealized mixture containing 80%TCP-20%HA (BoneSave™) in a
50/50 ratio with bone 
• HA80: idealized mixture containing 80%HA-20%TCP in a 50/50 ratio with
bone 
• HA80-3 sizes: partially idealized mixture containing 80%HA-20%TC  in a 
50/50 ratio with bone 
A,B: significant differences between groups (p<0.05) 
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8.5.2.  Histology 
 
Histological examination of defects implanted with allograft (“Bone”) showed that there was 
little remaining dead bone, with trabecular bone predominating. One defect designated “Bone” 
was devoid of all treatment material and was excluded from the study. No evidence of 
inflammatory response was present in this defect so it was assumed that the mixture had become 
dislodged at some point.  
 
The healing of defects treated with TCP-HA mixtures was less consistent, with variable 
proportions of trabecular bone, woven bone, and fibrous tissue being present. Appositional new 
bone was observed on the surface (Figure 45) and within the macropores of TCP-HA particles. A 
pronounced fibrocellular reaction was present in many defects, consisting of a mixed population 
of macrophages, giant cells, plasma cells, and fibroblasts. Cells near TCP-HA granules were 
frequently packed with grains of TCP-HA. 
 
 
 
Figure 45: Undecalcified 
sections of metaphyseal 
defects 14 weeks after 
implantation of tricalcium 
phosphate-hydroxyapatite 
particles (toluidine blue and 
basic fuscin, X100). 
 Top: particles surrounded by 
new bone  
Bottom: revascularization and 
incorporation of particles 
 66 
 
 
There was no evidence of bone cement penetration in any of the defects. Instead, the cement 
layer was separated from the defect by a fibrous tissue layer of variable thickness that was 
continuous with the periosteum. 
A significant level of agreement (p<0.001) occurred between the qualitative grades assigned by 
the two observers, allowing the scores for graft incorporation to be combined for statistical 
analysis (Figure 46). The mean score of 1.7 (± 0.2) for defects implanted with “HA80” was 
significantly lower than the mean score of 2.6 (± 0.2) for defects treated with allograft alone. 
There was a trend for “TCP80” (BoneSave™) and “HA80-3sizes” to have higher scores than 
“HA80”, but the difference did not reach significance.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
8.5.3.  Histomorphometry 
 
Defects treated with allograft alone (“Bone”) contained the highest proportion of bone elements, 
with a mean of 55.6 ± 4.1% of the defect area (Figure 47). The proportion of bone in defects 
treated with “HA80” was 38.0 ± 3.8%?, significantly less than in defects treated with allograft 
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Figure 46: Histological grades (mean) of metaphyseal defects filled with
impacted morselized grafts.  Grades increase from 1 to 3 with healing (mean
± Standard Error). 
• Bone: impacted idealized morselized allograft 
• TCP80: idealized mixture containing 80%TCP-20%HA  
(BoneSave™)  in a 50/50 ratio with bone 
• HA80: idealized mixture containing 80% HA-20%TCP in a 50/50 
ratio with bone 
• HA80-3sizes: partially idealized mixture containing 80%HA-
20%TCP  in a 50/50 ratio with bone 
* indicates a statistical difference between treatment groups 
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alone (p<0.05). There was a trend for defects treated with “TCP80” (BoneSave™) and “HA80-3 
sizes” to have a higher proportion of bone than “TCP20-HA80”, but the difference was not 
significant. 
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Figure 47: Histomorphometric analysis - percentage of the defect area filled
with bone and particles of synthetic agent (mean ± standard error). 
• Bone: impacted idealized morselized allograft 
• TCP80: idealized mixture containing 80%TCP-20%HA (BoneSave™),
in a 50/50 ratio with bone 
• HA80: idealized mixture containing 80% HA-20%TCP in a 50/50 ratio
with bone 
• HA80-3 sizes: partially idealized mixture containing 80%HA-20%TCP
in a 50/50 ratio with bone 
*
 indicates a statistical difference between treatment groups (p<0.05) 
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No significant difference was present in the amount of TCP-HA remaining at 14 weeks amongst 
defects grafted with “TCP80”, “HA80”, and “HA80-3 sizes” (Figure 47). 
 
 
8.5.4.  Bone fluorescence 
 
Mean mineral apposition rates for the early and late phase of graft incorporation are shown in 
Figures 48 and 49. No significant difference existed between treatments during early or late 
phases of defect healing (p>0.05). 
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Figure 48: Mineral apposition rates measured by the double pulse administration of 
oxytetracycline, administered 23 and 35 days after surgery, corresponding to the
“early” phase of incorporation (mean ± standard error).  
• Bone: impacted idealized morselized allograft 
• TCP80: idealized mixture containing 80%TCP-20%HA (BoneSave™) in a
50/50 ratio with bone 
• HA80: idealized mixture containing 80% HA-20%TCP in a 50/50 ratio with
bone 
• HA80-3 sizes: partially idealized mixture containing 80%HA-20%TCP in a
50/50 ratio with bone 
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Figure 49: Mineral apposition rates measured between the administrations of oxytetracycline and 
alizarin, administered 35 and 84 days after surgery, respectively, corresponding to the “late” phase of 
incorporation (mean ± standard error). 
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9.  DISCUSSION 
 
 
9.1. BIOMECHANICAL PROPERTIES OF BONE FROZEN IN SALINE 
 
Freezing of cortical allografts is a common method used for bone banking (Henry 1981, 
Denny 1985; Johnson 1988; Phillips et al. 1988; Ivory & Thomas 1993).  Storage 
temperatures below -80°C are required to inhibit enzymatic processes responsible for cellular 
degradation (Bright & Burchardt 1983; Tomford 1983; Tomford et al. 1987).  However, 
cortical specimens maintained at -20°C for several months have been used successfully in 
clinical cases (Henry 1981; Denny 1985; Sinibaldi 1989).  Freezing at -20°C for up to one 
year does not appear to alter the biomechanical properties of cortical allografts, if surface 
hydration of tissues is preserved (Bright & Burchardt 1983; Roe et al. 1988; Tshamala et al. 
1994).  In our study, metacarpal and metatarsal bones frozen with or without NSS had similar 
biomechanical properties in torsion.  In bending, the energy absorbed at failure by ribs and 
metacarpal and metatarsal bones stored in NSS was 25% to 30% greater than that of bones 
stored without NSS.  This means that a larger amount of energy was necessary to fracture 
bones stored with sodium chloride and that they were tougher than bones frozen without it 
(Chao & Aro 1991). The bending displacement at failure of corticocancellous grafts frozen 
with NSS was 18% to 24% greater than that of grafts frozen without NSS.  Ribs and 
metacarpal and metatarsal bones frozen without NSS are biomechanically more brittle.  The 
reason the torsion properties of the grafts stored without NSS were preserved while their 
bending strength decreased remains unclear.  Structural changes secondary to dehydration, 
such as different disposition of collagen fibers, may explain a selective decrease in the 
bending properties of these specimens. 
 
The effects of dehydration on biomechanical properties of cortical bone are of special 
importance when evaluating freeze-drying as a method of bone banking. Freeze-dried bone is 
brittle and must be reconstituted with saline solution before use (Brown & Cruess 1982).  
After rehydration, compression strength is regained (Bright & Burchardt 1983) or slightly 
increased (Pelker et al. 1984) compared with that for fresh controls, but the torsion (Pelker et 
al. 1983) and bending strengths (Triantafyllou et al. 1975) remain substantially lower.  
Cortical grafts stored in dry packages are often rehydrated in saline solution (Brown & Cruess 
1982; Denny 1985; Sinibaldi 1989; Johnson 1991; Stevenson 1991) immediately before 
transplantation, which may restore their biomechanical properties.  In our study, bones were 
tested immediately after thawing and before rehydration to evaluate the effects of the storage 
technique alone. 
 
Dehydrated bones have been reported to be brittle, hence, susceptible to splitting or flaking 
during placement of screws to immobilize the graft. Studies evaluating the effects of ethylene 
oxide sterilization and storage conditions on canine femora found a positive relation between 
available water and handling characteristics of bone undergoing drilling and tapping followed 
by seating of a cortical bone screw (Johnson et al. 1987). Use of polyethylene tubing was 
more efficient in preserving bone hydration than plastic film, paper, or plastic wrapping 
(Johnson et al. 1987).  In our study, bones frozen in plastic packs without NSS were probably 
less tough and more brittle as a result of dehydration. Addition of NSS improved preservation 
of biomechanical properties of corticocancellous grafts.  Freezing bone in NSS may be an 
alternative to use of polyethylene tubing as a packaging technique. 
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9.2. OSTEOPRODUCTIVE PROPERTIES OF A BONE-INDUCING AGENT IN 
DOGS 
 
Isolation and purification of a bone-inducing agent from an established human cell line would 
provide an unlimited supply of osteoinductive bone graft substitute.  Osteoinductive activity 
has been found in several animal (Takaoka et al. 1993) and human (Yan & Lianjia 1990; 
Htakeyama et al. 1993) neoplasms, but only a few of those have been established as cell lines 
(Fogh & Trempe 1975, Takaoka et al. 1989, Anderson et al. 1992).  Live and freeze-dried 
neoplastic cells maintained in culture may induce bone formation after heterotopic 
implantation (Takaoka et al. 1989; Htakeyama et al. 1993).  These preparations may also be 
carcinogenic (Htakeyama et al. 1993).  This risk is reduced if the osteoinductive agent 
contained in the cells is extracted and purified.   BIA has been extracted from Saos-2 human 
osteosarcoma cells.  BIA contains a mixture of bone growth factors, most likely BMP-1, 2, 3, 
4, 6, and Transforming Growth Factor-ß (TGF-ß) (Raval et al. 1993; Anderson et al. 1995).    
 
In the study reported here, we confirmed the osteoinductive properties of BIA as it induced 
bone formation in muscle.  Confirmation of osteoinductive properties of a bone-inducing 
agent requires ectopic implantation in a site void of osteoprogenitor cells.  Muscle and 
subcutaneous tissue are the prevailing sites of implantation for osteoinductive bioassays.  The 
latissimus dorsi muscle was selected for the osteoinductive bioassays because it is easy to 
expose and offers a large section of muscle of similar thickness.  Bone formation is usually 
detected within two weeks after heterotopic implantation of an osteoinductive agent in 
athymic mice.  In monkeys and dogs, osteoinductive bioassays are usually prolonged to six to 
eight weeks (Sato & Urist 1985; Miyamoto et al. 1993) to compensate for their slower 
metabolic rate compared to rodents (Coulson 1983; Sato & Urist 1985; Cook et al. 1994).  
The lack of bone formation after ectopic implantation of autogenous cancellous graft is in 
agreement with previous studies: nondecalcified bone transplants are minimally 
osteoinductive and generate the production of multinucleated cells (Chalmers et al. 1975; 
Nade 1979).  
 
Although heterotopic implantation is necessary to determine the osteoinductive properties of a 
substance enhancing bone healing, the response to orthotopic implantation is more clinically 
pertinent (Kirker-Head 1995).  Surgically created cortical bone defects have been used in dogs 
(Elkins & Jones 1988; Howard et al. 1988; Trevor et al. 1992; Forell & Straw 1993) to 
evaluate the effects of various treatments on bone healing.  This model does not necessitate 
fixation and allows for evaluation of several local factors on the same bone.  To limit variation 
of results due to location of the defects, all four defects were created in the diaphysis of a long 
bone and assigned to treatments according to a Latin square design.   
 
The histological grades of the defects filled with autogenous cancellous bone are consistent 
with previous reports (Elkins & Jones 1988), with three of four defects being entirely filled 
with bone.  Three of the four defects filled with a gelatin capsule alone had healed, whereas 
none of the defects treated with BIA had healed eight weeks after the operation.  BIA 
stimulates early osseous union of a femoral nonunion in rats (Hunt et al. 1993), but 10 mg of 
BIA did not promote healing of cortical defects in dogs; no bone formation was found six 
weeks after intramuscular implantation of BIA.  The failure of bone induction may be 
explained by faulty osteoinductive properties of the agent, an inadequate delivery of the agent, 
or the inability of dogs to respond to bone inductive stimuli that are effective in rodents.    
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For effective osteoinduction, osteogenic proteins must be implanted with an appropriate 
carrier substance since they are water soluble and readily diffusible. (Wozney 1993).  The 
functions of the carrier include releasing the osteoinductive agent at an effective dose 
simultaneously with the accumulation of target cells, possibly protecting osteoinductive 
proteins against nonspecific proteolysis, and accommodating each step of the cellular 
response during bone formation.  The carrier must also be biocompatible and biodegradable, 
and it should ideally provide a substrate for the attachment of recruited cells and blood vessel 
ingrowth (Cook et al. 1994).  To evaluate the osteoinductive properties of an agent, the carrier 
must also be deprived of such properties.  Pure bovine collagen type I did not induce ectopic 
bone formation in dogs.  It is believed to act as a slow-release protein delivery system, 
improving the osteogenic potential of purified BMP in vivo (Bessho & Lizuka 1994).  Bovine 
collagen has been used as a carrier for osteoinductive preparations in dogs (Cook et al. 1994) 
and failed to inhibit the osteoinductive properties of BIA in rodents.  Therefore, the presence 
of bovine collagen type I is unlikely to account for the failure of BIA to induce bone 
formation in dogs.   
 
The lack of osteoinductive effects of BIA after heterotopic and orthotopic implantation in the 
dog may be related to the dose of BIA used in this study.  Induced bone formation is a dose-
related phenomenon (Urist et al. 1987; Wozney et al. 1988; Gao et al. 1993).  It has been 
suggested that in larger animals with longer lifespans, such as dogs, sheep, and monkeys, only 
bone and bone marrow contain perivascular mesenchymal cells able to respond to bone 
inductive signals (Nade & Burwell 1977; Sato & Urist 1985; Aspenberg et al. 1991).  As a 
result, osteoinductive bioassays are generally performed in rodents and osteoinductive 
preparations are commonly evaluated in orthotopic sites in animals with a long lifespan (Sato 
& Urist 1985, Nilsson et al. 1986).  Recent studies suggest that "long-lived" vertebrates retain 
extraskeletal inducible cells (Vail et al. 1994) and osteoinductive proteins in the extracellular 
matrix of bone (Forell & Straw 1993) but that the regenerative capacity of mammalian bone is 
inversely proportional to position on the phylogenetic scale (Aspenberg et al. 1992; Miyamoto 
et al. 1993; Cook et al. 1994). Higher vertebrates with a longer lifespan are less sensitive to 
osteogenic proteins than rodents.  Nilsson et al. (1986) reported that 100 mg of partially 
purified bovine BMP, implanted in a gelatin capsule, induced radiographic healing of a canine 
ulnar defect at an average of 12 weeks.  However, similar results were obtained with 625 µg 
of pure recombinant human morphogenetic protein-7 in the same nonunion model (Cook et al. 
1994).  The optimal dose of osteoinductive agent varies not only with the site and species of 
implantation but also with the nature of the agent (Sato & Urist 1985; Takaoka et al. 1993).  
BIA is sufficiently potent that doses as low as 1 mg induce ectopic bone formation in mice 
(Anderson et al. 1995), but dogs may require more than 10 mg of BIA to respond.  Thus, 
evaluation of higher doses of BIA is indicated.  The difference in results obtained after 
implantation of BIA in rodents versus dogs may also be related to immunogenic factors.  The 
exact nature of the osteoinductive proteins in the extracellular bone matrix of different species 
is unknown, but the ability of demineralized bone matrix (DBM) to induce bone formation 
appears somewhat specific (Nilsson & Urist 1991; Forell et al. 1993).  Athymic mice are 
suitable models for the osteoinductive bioassay of xenogeneic preparations because they are 
deprived of T-lymphocytes to initiate an immunogenic response to foreign material.  Anti-
BMP immunoglobulins were found in the serum of pigs two to three weeks after implantation 
of partially purified bovine bone morphogenetic protein fraction and associated 
noncollagenous proteins (Lindholm et al. 1994).  An inflammatory response was initiated by 
implantation of demineralized bone matrix from various species in the rat, resulting in a lack 
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of osteoinduction (Sampath & Reddi 1983).  Further purification of this xenogenic bone 
matrix and extraction of low molecular weight, noncollagenous proteins resulted in ectopic 
bone formation in the rat (Sampath & Reddi 1983).  The bone morphogenetic protein fraction 
from diverse mammalian species is believed to consist of several homologous subunits 
(Bessho et al. 1992; Wozney 1993; Cook et al. 1994).  The species specificity of bone 
induction is most likely attributable to immunogenic or inhibitory proteinaceous impurities 
(Sampath & Reddi 1983; Forell et al. 1993; Cook et al. 1994).  BIA is a semi-purified agent, 
extracted from human cell lines, and further purification may be necessary to prevent an 
immunogenic response and allow osteoinduction in the dog. 
 
 
9.3. EVALUATION OF AN OVINE MODEL TO TEST IMPACTED AGGREGATES 
 
Unicortical bone defects are well-established models for evaluation of the biological 
properties of grafting materials.  One of their limitations is related to the size of the defect and 
the risk of fracture secondary to a stress rising effect. Diaphyseal defects involving 20% of the 
diameter of the bone decrease the torsional strength by 34% (Edgerton et al. 1990).  Whereas 
previous studies describe the use of diaphyseal unicortical defects measuring up to 9 mm in 
diameter in sheep (Frayssinet et al. 1993), the metaphysis of long bones can accommodate 
larger defects (Sartoris et al. 1986; Sauk & Van Kampen 1991).  In our study, 15-mm-
diameter metaphyseal defects were created to evaluate a representative sample of our 
aggregates, including particles up to 5 mm in diameter.  The four femoral fractures observed 
in Study IV most likely resulted from the stress-rising effect created by the proximal and 
distal femoral defects. Limiting the number of defects to one per long bone and selecting 
larger sheep eliminated this complication in study V.  
The other reason for selecting the metaphysis as the site of implantation was related to the 
balance between osteogenesis and biodegradation of grafting materials in cancellous bone.  Lu 
et al. (1998) recently compared tissue reactions to calcium phosphate ceramics among 
cancellous, cortical, and medullar implantation sites in rabbits: medullar sites exhibited a 
stronger immune response and faster biomaterials degradation, whereas osteoproduction was 
increased within cortical sites.   Cancellous sites had intermediate activities and were 
therefore recommended as models for evaluation of the properties of biomaterials.  
Defects were covered with polymethylmethacrylate to simulate the environment of cemented 
revision hip arthroplasty, maintain the degree of impaction, and prevent migration of the 
pellets.  Although grafting material was identified within all defects containing allograft, the 
cement seal migrated in 24.2% of defects in Study IV, while no migration was noted in Study 
V. The migration of cement seals in Study IV suggests that the amount of 
polymethylmethacrylate engaging empty screw holes was too small to maintain the plug in 
position. Embedding Kirshner wires was more effective than pouring liquid 
polymethylmethacrylate over empty screw holes in preventing migration of cement seals.   
Although no difference was found between right and left limbs throughout the study, the site 
of implantation seemed to affect the incorporation of grafting material and healing of the 
defects.  In Study IV, distal femoral defects contained more bone and less fibrous tissue than 
defects located in the proximal tibia seven weeks after surgery.  Proximal femoral defects 
seemed to behave in way similar to distal femoral defects, but the depth of the 
intertrochanteric fossa in sheep is such that 15-mm-deep defects distal to the greater 
trochanter extended into the far cortex.  Because this may affect the degree of compaction of 
pellets placed in that position, this site of implantation was eliminated in Study V.  No 
difference was found between sites in terms of incorporation of grafting material, but the 
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synthetic agent evaluated in Study IV was completely resorbed in all defects but one, seven 
weeks after implantation.  Similar findings were noted 14 weeks after surgery in Study V, 
where distal femoral defects obtained higher histological grades than tibial sites.  Although 
this was not statistically significant, the amount of bone found within defects was greater in 
the distal femur than the proximal tibia.  These results would suggest that defects heal faster 
in the former.  However, the amount of synthetic agent was also higher in the distal femur 
than proximal tibia.  These results correlate well with computed tomographic data, as particles 
of the agents tested in Study V were denser than allograft. The slower degradation of 
biomaterials and greater osteoproduction in distal femoral sites as compared with proximal 
tibia may be explained by a difference in tissue composition.  Although this was not 
specifically measured, distal femoral sites appeared to contain more cancellous bone, whereas 
proximal tibial defects were closer to the medullar cavity.  This would confirm previous 
studies in rabbits, where medullar sites exhibited faster degradation of biomaterials and less 
osteoproduction than cancellous sites (Lu et al. 1998).  Our findings further suggest that the 
distal femur is a better site than the proximal femur and tibia to evaluate impacted morselized 
aggregates containing large particles in unicortical defects.  However, this limits the number 
of treatment groups evaluated on the same animal.  If different implantation sites are used 
within the same study, allocation of treatment to defects should follow a Latin square design 
to evaluate each treatment in all locations and eliminate variation due to position.    
Mineral apposition rates measured within defects were overall 50% higher than remodeling 
rates 4 weeks after surgery, and decreased by 12 weeks in both phases of the study.  In Study 
V, mineral apposition rates measured at 4 weeks were greater at the center than the periphery 
of the defect.  This may reflect the progression of healing in unicortical bone defects, where 
bone formation proceeds from the periphery toward the center (Schenk & Hunziker 1994).  
Measurements obtained along the edges of the defect may therefore represent a more mature 
phase of healing, with lower mineral apposition rates than in the centre of the defect.  To 
standardize our measurements, mineral apposition rates were obtained at the periphery of the 
superficial aspect for each implantation site in Study IV.  In Study V, measurements obtained 
in four locations within each defect were averaged to compare treatments. 
Although the model simulates some of the environmental characteristics encountered in 
impaction grafting for revision hip arthroplasty, it does not reproduce the mechanical loading 
generated in clinical cases.  Biomechanical loading has recently been shown to affect the 
incorporation of morselized bone graft in a unicortical bone defect (Lamerigts et al. 2000).  In 
this model, controlled compression was applied over the defect area, whereas grafting 
material impacted around a femoral stem is exposed to a combination of compression and 
shear forces.   
 
 
9.4. BIOLOGICAL PROPERTIES OF A SILICATE-FREE BIOACTIVE GLASS 
 
Although site of implantation has been found to influence the osteoproduction and 
degradation rate of implants (Lu et al. 1998 and section 9.3.), randomization of treatment 
allocation according to a Latin square design allows us to compare treatment groups.  Our 
results suggest that healing of metaphyseal defects tended to decrease with increasing 
concentrations of Corglaes®.  Defects filled with 50/50 or 100% Corglaes® contained more 
fibrous tissue and less bone than defects filled with bone 14 weeks after implantation.  
Removal of Corglaes® particles consists of chemical dissolution, resulting in an acidic 
environment (Gilchrist et al. 1991).  It is possible that rapid dissolution of high concentrations 
of Corglaes® (50% or 100%) overwhelmed the physiologic buffering systems and resulted in a 
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decrease of local pH, stimulating osteoclastic activity and affecting healing of the defects 
(Hruska et al. 1993).   Allograft also compared favorably to synthetic agents in other studies, 
justifying its use as a control (Moore et al. 1987; Virolainen et al. 1997).  However, 
limitations associated with the use of allografts may eventually outweigh the benefit of higher 
osteoproductive properties.  Interestingly, none of the parameters evaluated in our study 
differed between defects filled with allograft and those filled with allograft idealized with 
Corglaes®.  This mixture, containing approximately 25% Corglaes®, would have the 
biomechanical advantage of improved resistance to shear compared with allograft, and 
therefore warrants further evaluation.  
Our results also suggest that morselized Corglaes® was nearly dissolved by seven weeks after 
impaction in sheep metaphyseal defects.  Indeed, remnants of bioactive glass were found in 
only one defect, seven weeks after implantation.  There was no evidence of synthetic agent at 
14 weeks.  Incorrect sectioning or migration of pellets seem unlikely since particles of dead 
bone were identified in all defects containing allograft alone, or mixed with the synthetic 
agent.  This early dissolution would explain the computed tomography findings.  Although 
pellets containing Corglaes® had higher pixel values than allograft pellets prior to 
implantation, defects treated with 50% or more Corglaes® were less dense than defects filled 
with allograft, seven weeks after surgery. The incorporation of Corglaes® in our study seems 
faster than that of previously evaluated bioactive glasses (Gao et al. 1995; Schepers & 
Ducheyne 1997; Hench 1998).  However, properties of bioactive glasses are influenced by 
their composition, manufacturing process, and presentation. The main difference between the 
controlled release glass (CRG) evaluated in our study and previous bioactive glasses is that it 
contains biodegradable P2O5 rather than SiO2 as a network former.  A typical CRG will 
comprise 42-49 mole% of P2O5, the remainder as 10-40 mole% of CaO and Na2O.  Variation 
in ratios and addition of various compounds can be used to adjust the dissolution rate.  For 
example, increased levels of CaO, decreased concentrations of Na2O, and fluoride additions 
will slow the dissolution of the compound (Burnie & Gilchrist 1983; Hench 1998).  Annealing 
temperature is one aspect of the manufacturing process that will affect the longevity of 
biodegradable implants, with higher temperatures slowing the degradation of calcium 
phosphate fibers (Choueka et al. 1995).  Granulometry has also been shown to influence the 
biological properties of bioactive glass (Schepers & Ducheyne 1997) as well as other ceramics 
(Malard et al. 1999): smaller particles were associated with faster degradation and higher 
osteoconductive properties.  Therefore, an aggregate combining particles of different sizes 
could potentially benefit from prolonged osteoconduction associated with a gradual 
degradation process.  The other advantage consists of improved biomechanical properties 
associated with increased cohesion between particles, when their size distribution follows the 
ideal linear logarithmic grading line (Brewster et al. 1999).  The ideal integration rate of grafts 
used in revision hip arthroplasty has not been determined but should probably be longer than 
seven weeks to allow gradual replacement by new bone and remodeling.  Degradation of 
grafting material may however be slower along the smooth, poorly vascularised endosteal 
surface of a revised femoral diaphysis compared with the normal metaphyseal cancellous 
bone in our study.  Differences in osmotic fluxes, vascularity, and biomechanical loads 
between our model and the clinical setting may also influence the incorporation of synthetic 
agents (Tagil 2000).  
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9.5. OSTEOCONDUCTIVE PROPERTIES OF IMPACTED MORSELIZED 
TRICALCIUM PHOSPHATE-HYDROXYAPATITE 
 
A metaphyseal defect model was selected for this study to allow preliminary evaluation of the 
biological properties of several agents within the same animal. This model is technically 
simple to use and, while simulating some of the environmental characteristics encountered in 
revision hip arthroplasty (contact with cancellous bone and cement, impaction of grafting 
materials), is not intended to mimic the loading conditions encountered clinically. Although 
site of implantation has been found to influence the osteoproduction and degradation rate of 
implants (Lu et al. 1998 and section 9.3.), randomization of treatment allocation allows us to 
compare treatment groups.  
Corticocancellous allograft was chosen as one treatment since it is currently used in human 
impaction grafting. Idealized, impacted corticocancellous allograft was well incorporated 
within metaphyseal defects: by 14 weeks, the original trabecular architecture had been 
restored and the majority of dead bone had been removed or remodeled. The larger remaining 
fragments tended to be remnants of morselized cortical bone. The presence of cortical bone is 
not necessarily undesirable since it may contribute to the stability of the aggregate as the 
allograft becomes incorporated. Our results compare favorably with other experimental 
studies using impacted allograft (Tagil & Aspenberg 1998; Lamerigts et al. 2000; Tagil 2000).  
The mean CT-derived density of defects treated with allograft alone was significantly lower 
than that of defects treated with mixtures containing synthetic agents. The higher density of 
TCP-HA granules as compared with morselized allograft can explain these results. No 
significant difference in density was seen between the three TCP-HA expanded mixtures. 
Similarly, there was no significant difference in the mean percentage of residual synthetic 
implants within defects. These two results suggest that the dissolution rate for 80%TCP-
20%HA is similar to 80%HA-20%TCP at 14 weeks. We expected 80%TCP-20%HA to be 
removed more rapidly since TCP is more soluble than HA in tissue fluids. However, both of 
these materials are ceramics, which, like HA are relatively inert and mostly removed by 
cellular processes (Lamerigts et al. 2000). On histological examination, little difference was 
found in the degree of cellular degradation between the different ceramic mixtures, and 
particles were seen within phagocytic cells in all defects treated with TCP-HA mixtures.     
Our results confirm that corticocancellous allograft expanded with TCP-HA particles was 
osteoconductive. However, the degree of incorporation within and between TCP-HA 
treatment groups was variable and less consistent than for allograft alone. The lowest 
histological grades and proportion of bone within the defect were obtained with the fully 
idealized mixture of particles containing 80% HA.  On the other hand, no difference was 
found between sites implanted with a fully idealized mixture of particles containing 80% 
TCP, the partially idealized mixture (3 sizes) containing 80% HA, and the positive control 
(allograft). 
There was a trend for particles containing 80% TCP to have a higher mean incorporation 
grade and more bone within defects than particles rich in HA. Both of these mixtures were 
idealized, but differed in the relative proportions of TCP and HA. A higher proportion of the 
more soluble TCP appears to improve osteoconduction. Our results conflict with the results of 
a study evaluating biphasic calcium phosphate granules for repair of periodontal osseous 
defects, where 15%TCP-85%HA granules gave superior results to all other ratios of TCP to 
HA that were evaluated (Frayssinet et al. 1993). 
In the present study, we also applied the concept of “idealization” to impacted test mixtures. 
Compaction of conventional allograft may cause a transitory reduction in osteoconduction 
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(Tagil et al. 1998; Tagil 2000).  Idealization increases cohesion between particles and may 
therefore impair incorporation of the graft as well as its osteoconductive properties.  Defects 
filled with a mixture idealized with three particle sizes (partially idealized) tended to reach a 
higher mean histological grade and contained more bone than sites implanted with a mixture 
idealized with eight particle sizes. The chemical composition of the TCP-HA granules was 
identical and the two mixtures differed only by the degree of idealization. This suggests that a 
less stringent idealization process may enhance osteoconduction, possibly because the 
structure of the mixture is more “open”.  A mixture prepared with particles of three sizes 
instead of eight is also easier to manufacture.  A partially idealized mixture of particles 
containing 80% TCP studies warrants further evaluation in a hemiarthroplasty model, 
simulating the loading conditions encountered clinically (Blom et al. 2001).   
 
 78 
!". CONCLUSIONS# CLINICAL SI$NIFICANCE# AND FUTURE DIRECTIONS 
 
 
Study I: 
 
In the first study, bones frozen in plastic packs without normal saline were probably less tough 
and more brittle as a result of dehydration. Addition of isotonic saline solution improved 
preservation of biomechanical properties of corticocancellous grafts.  Freezing bone in normal 
saline solution may be an alternative to use of polyethylene tubing as a packaging technique. 
 
Clinical significance: 
Results of this study suggest potential benefits in long-term freezing of corticocancellous bone in 
isotonic saline solution. Ribs and metacarpal and metatarsal bones stored in normal saline 
solution were comparatively tougher and less brittle than grafts stored without isotonic saline, 
when tested to failure in bending.  However, biomechanical testing of cortical bone differs from 
the clinical situation because it does not address ongoing biological processes associated with 
revascularization, incorporation, and remodeling of the graft. 
 
Future directions: 
Secondary sterilization of bone allograft by gamma irradiation affects the biomechanical 
properties of bone allograft. Bone irradiated at 30 kGy, which is the dose recommended to 
inactivate HIV (Fideler et al. 1994), becomes so brittle that it cannot be used as a structural graft 
(Pelker & Friedlander 1987).  These changes result from the dose-dependent effect of irradiation 
on the plastic properties of collagen. Radiation produces reactive free radicals by radiolysis of 
water, which damages collagen alpha chains (Stachowicz et al. 1970).  The effects of irradiation 
and the degree of inactivation of HIV in culture may vary with factors such as temperature.  In a 
recent study, bone irradiated at -78°C (i.e. frozen) was less brittle and sustained less collagen that 
when irradiated at room temperature (Hamer et al. 1999). It would be interesting to study whether 
immersion in saline solution would improve the effects of irradiation and decrease the dose 
required for HIV inactivation, thus preserving the biomechanical properties of allogenic bone.   
 
 
Study II: 
 
Ten milligrams of the bone-inducing agent extracted from a human osteosarcoma cell-line (Saos-
2) was not osteoinductive and did not promote bone healing after orthotopic implantation in dogs.  
The difference between these results and those obtained in rodents may be related to an immune 
reaction or an insufficient dose of BIA.  The human origin of BIA may have been the source of 
immunogenical factors, inhibiting osteoinduction in dogs.  
 
Clinical significance: 
Although the human origin of BIA may be an advantage for use in man, further evaluation in 
immunocompetent higher vertebrates is warranted prior to human clinical trials.  Such tests could 
involve higher doses of the agent or evaluation in nonhuman primates.  
Further to this study, tests confirmed the presence of immunogenic impurities in the preparation. 
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Future directions: 
The culture medium of Saos-2 cells appears osteoinductive in rodents (Anderson HC, personal 
communication).  This may represent an even more effective and potentially safer (the medium 
does not contain neoplastic cells) method to produce a mixture of growth factors and warrants 
further investigation. 
This project has generally raised my interest in osteoinductive factors present in bone tumors. 
Whereas significant research has focused on the relationship between bone morphogenetic 
proteins and neoplastic bone diseases in man (Bauer & Urist 1981; Yan & Lianjia 1990; 
Yoshikawa 1994 a,b), very little has been done in veterinary medicine.  A comparative study of 
the expression of BMPs in canine and feline osteosarcoma would open up an unlimited field of 
research.  For example, it would be interesting to determine whether the presence of BMP activity 
in small animal osteosarcoma has the same prognostic value as in man (Yoshikawa et al. 1985, 
1988).  This type of study could have consequences on the clinical management of bone tumors. 
 
 
Study III: 
 
We describe a model for preliminary evaluation of the biological properties of impacted 
morselized grafts previously studied in vitro, and considered for use in revision hip arthroplasty.  
This model does not require internal fixation, optimizes the use of animals, and accommodates 
aggregates consisting of large particles.  Whereas no difference was found between left and right 
limbs, osteogenesis and incorporation of biomaterials varied between implantation sites. 
Treatment site allocation should therefore be randomized according to a Latin square design for 
comparison of grafting materials.  The distal femur provided the best location in our study as it 
subjectively contained more cancellous bone than the proximal tibia and provided an intact far 
cortex compared with the proximal femur.  Only one defect (15 mm in diameter and depth) 
should be created in each long bone (femur and tibia) to prevent postoperative fractures.  
Idealized morselized impacted allograft provides a positive control for comparison of treatment 
groups using computed tomography, histology, and histomorphometry.  The location for 
measuring mineral apposition rates should be standardized within each defect. 
 
Clinical significance: 
This model is particularly useful for selecting grafting materials prior to evaluation in a 
hemiarthroplasty model, simulating the loading conditions encountered clinically.  
A mixture of Corglaes®  and allograft is currently being tested in an ovine hemiarthroplasty model 
(Dunlop & Field 2000).  On histological evaluation of a few specimen, particles of bioactive glass 
are seen near the distal end of the stem (femoral diaphysis), whereas no synthetic agent can be 
found in the proximal femoral canal at 14 weeks after implantation (Figure 50).  This preliminary 
data suggests that the behaviour of grafting material may be similar in the ovine metaphyseal 
defect model and the proximal femur after impaction grafting hip arthroplasty. 
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Evaluation of bioactive glass 
in an ovine hemiarthroplasty
 
Figure 50: Radiograph, gross appearance, and histology of an ovine femur 14 
weeks after impaction grafting hemiarthroplasty.  A collarless polished tapered 
femoral stem (with centralizer) was implanted after impaction of a 50/50 
allograft/bioactive glass idealized mixture in the femoral canal.  Particles of 
bioactive glass are only found near the distal end of the implant. (Courtesy of D 
Dunlop). 
 
 
Study IV: 
 
Corglaes® implanted in ovine metaphyseal defects was resorbed faster than predicted in vitro, 
within 7 weeks, which is too fast for use in impaction grafting arthroplasty.  Healing of defects 
containing 50% or 100% synthetic agent was poorer than defects treated with allograft.  On the 
other hand, no difference was found between sites implanted with bone (autograft or allograft) 
and allograft idealised with Corglaes®.  
 
Clinical significance: 
Further evaluation of Corglaes® is warranted before clinical trials may be considered.   
Based on our results, evaluation of an idealized mixture of bone and Corglaes® in a 
hemiarthroplasty model, which would reproduce the biological and biomechanical conditions 
encountered clinically seems warranted.  If our results are confirmed, the composition and/or 
manufacturing process of the compound tested in our study should be revised before it can be 
considered for impaction grafting in revision hip arthroplasty.   
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Future directions: 
The dissolution rate of the agent tested is compatible with the delivery of local growth factors and 
antibiotics.  It may therefore be considered as a potential carrier for local delivery of antibiotics in 
skeletal tissues, as described for traditional bioactive glasses (Otsuka et al. 1995), and is already 
used in other medical devices as a broad-spectrum antimicrobial metal ion delivery system, 
shown in Figure 51 (Gilchrist et al. 1991). 
 
 
 
 
 
Based on the results of this study, the manufacturer has modified the attenuation factor used to 
predict in vivo dissolution rate based on in vitro tests.  The composition of the agent is also 
modified to produce a glass that should dissolve in about six months after implantation.  in vivo 
evaluation of the new agent will be indicated to verify its biological properties.  There is some 
evidence to suggest that particles of traditional bioactive glass measuring less than 300 µm may 
be more osteoconductive than larger particles (Schepers et al. 1991; Nasr et al. 1999).  It would 
therefore be interesting to evaluate whether the addition of smaller particles (less than 300 µm) of 
silicate-free glass to an idealized mixture would influence its properties.  Another pole of research 
interest focuses on the production of osteoconductive fibers.  Although it has not been confirmed, 
this presentation may increase osteoconductive properties of bone graft substitutes and modify 
their biomechanical properties.  None of the polymer-coated bioactive glass (silicate-free) fibers 
produced has been evaluated for orthopedic use.  
 
 
Study V: 
 
Implantation of idealized, impacted, morselized allograft resulted in healing of defects at 14 
weeks. Impacted, idealized mixtures have been shown elsewhere to have superior biomechanical 
properties when compared with conventionally impacted allograft (Brewster et al. 1999). 
Expanding allograft with tricalcium phosphate - hydroxyapatite granules to produce an idealised 
mixture offers many advantages and shows promise. Partially idealizing the mixture may improve 
graft incorporation, with implications for easier manufacture.  Particles containing 80% 
tricalcium phosphate tended to be more osteoconductive than particles containing 80% 
hydroxyapatite.  Additional studies are in progress to determine the long-term behavior of these 
mixtures under realistic loading conditions in a sheep arthroplasty model (Blom et al. 2001). 
 
Figure 51: Buttons of Corglaes loaded 
with antimicrobial agents such as zinc, 
copper, or silver. 
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Clinical significance: 
Particles containing 80%TCP-20%HA have been approved for use in Europe.  The agent is 
currently being launched as an allograft expander for impaction grafting hip arthroplasty under 
the name of BoneSave. It is available in two size ranges: 2- to 4- mm-diameter particles are 
recommended for use in femoral impaction grafting, whereas 4- to 6- mm-diameter particles are 
recommended for use in acetabular impaction grafting.  BoneSave is now undergoing clinical 
trials in selected centers throughout Europe. 
 
Future directions: 
The agent may be considered for use in impaction grafting knee replacement. Another direction 
of research may focus on its use as a carrier for local growth factors.  Although, collagen has 
been the most common delivery system for BMPs, its biomechanical properties preclude its use 
as a graft expander in impaction grafting (Lindholm & Gao 1993; Wolfe & Cook 1994; Ladd & 
Pliam 1999).  On the other hand, synthetic ceramics have been used as carriers for BMPs (Herr et 
al. 1993; Lindholm & Gao 1993; Ripamonti 1993; Hotz & Herr 1994; Laffargue et al. 1999; Tay 
et al. 1999).  It would therefore be interesting to evaluate the applicability of TCP-HA augmented 
with rhBMP-2 in impaction grafting.  Because the implants used in impaction grafting hip 
arthroplasty are most frequently cemented, a preliminary study should be aimed at measuring the 
minimum distance from heat-generating bone cement required to preserve the osteoinductive 
properties of a graft. 
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